Acknowledgements

The Texas Diabetes Council wishes to thank the following individuals who have contributed to the development and ongoing review of the *Diabetes Tool Kit*.

**5TH EDITION (2009) AUTHORS/EDITORS**

- Luby Garza-Abijaoude, MS, RD, LD
- Shannon I. Brow, RN, CDE, FNP-C
- Shane Greene, Pharm. D, BCPS, CDE
- Priscilla Hollander, MD, PhD
- Lance Sloan, MD, FACE
- Craig W. Spellman, PhD, DO
- Curtis Triplitt, PharmD, CDE, BCPS
- Evangelina T. Villagomez, PhD, RN, CCRN, CDE, CS
- Barbara K. Walz, RN, BSN, CDE
- Kathleen L. Wyne, MD, PhD, FACE
- Susan Young, MSN, RN

**PREVIOUS CONTRIBUTORS**

- Luby Garza-Abijaoude, MS, RD, LD
- N. Alteza, RN, BSN
- Jim Aycock, PT
- Mohammed M. Bakdash, MD
- Elda Balle, RD, LD, CDE
- A.J. Bell, RN, BSN
- Micky Bielamowicz, PhD, RD, LD
- Shannon I. Brow, RN, CDE, FNP-C
- Olivia Charlton, RD, LD
- Joan Colgin, RN, BSN, CDE
- Jaime Davidson, MD
- Yolanda Gonzalez, RN, CDE
- Carolyn M. Grubb, RD, LD, CDE
- Lawrence B. Harkless, DPM
- S. Hill, RN, CDE
- Priscilla Hollander, MD, PhD
- Jeffrey A. Jackson, MD, FACP, CDE
- Donna Jones
- John A. Menchaca, MD
- Douglas P. Murdock, DPM, FACFAS
- O. Oviedo, RN, MSN, CDE
- Jan Ozias, PhD, RN
- Ana Pacheco, RD, LD, CDE
- Linda Quattrone, RN, CDE
- Molly Rodriguez, PhD, RN, CDE
- C. Saavedra, RN
- Lita Silva, RN, MSN, CDE
- Lance Sloan, MD, FACE
- Craig W. Spellman, PhD, DO
- Curtis Triplitt, PharmD, CDE, BCPS
- Kathleen King-Tryce, RN, MSN
- Surendra K. Varma, MD
- Hector Verastegui, RN, CDE
- Sara Villegas, RN, CDE
- Evangelina T. Villagomez, PhD, RN, CCRN, CDE, CS
- Barbara K. Walz, RN, BSN, CDE
- Aimee D. Wauters, MS, RD, LD, CDE
- Susan Young, MSN, RN
- Virginia Zamudio, RN, MSN, CDE
Diabetes Tool Kit Survey

The Diabetes Tool Kit is revised every year. Please complete the survey so that we can improve the information and resources you find most valuable! Your responses to the questions below are optional; however, your feedback will enable us to determine if we are providing the most useful information and if we are reaching our intended audiences. Thank you!!

1. How did you learn about the Diabetes Tool Kit? (Choose one)
   - Healthcare provider
   - The Texas Diabetes Council Web site
   - DSHS (Dept. of State Health Services) Literature & Forms Catalogue
   - Professional CE event/workshop/exhibit at a conference
   - Person with diabetes
   - Other (please describe):

2. How long have you been using the Tool Kit?
   - <1 year
   - 1-3 years
   - >3 years

3. What format do you use most often?
   - CD
   - Hardcopy
   - Web site

4. What sections/topics in the Tool Kit do you use the most? (Choose all that apply)
   - Minimum Practice Recommendations (flow sheet)
   - Treatment Algorithms / Guidelines
   - Pregnancy and Diabetes
   - Monitoring
   - Nutrition
   - Exercise
   - Medications
   - Acute Complications
   - Chronic Complications
   - Psychosocial Issues
   - Resource Lists
   - Patient Handouts

5. What sections/topics of the Tool Kit do you use the least? (Choose all that apply)
   - Minimum Practice Recommendations (flow sheet)
   - Treatment Algorithms / Guidelines
   - Pregnancy and Diabetes
   - Monitoring
   - Nutrition
   - Exercise
   - Medications
   - Acute Complications
   - Chronic Complications
   - Psychosocial Issues
   - Resource Lists
   - Patient Handouts

6. What information would you like to see included in the Tool Kit? or What changes could be made to improve the Tool Kit?

7. In what Texas county do you reside?

8. Which group (s) represents your primary patient population (Choose all that apply)
   - Asian
   - Hispanic/Latino
   - Black
   - White
   - Native American
   - Other (please specify: ____________________)

9. Please indicate the type of healthcare provider you are:
   - Physician assistant
   - Primary care physician
   - Registered Dietitian
   - Registered Nurse
   - Advanced Practice Nurse
   - Certified Diabetes Educator
   - Hospitalist
   - Specialist (please indicate specialty: ____________________)
   - Other (please specify: ____________________)

II
10. Please indicate which algorithms, treatment(s), therapies, and/or protocols you use in your practice (check all that are used):

- Weight Loss for Overweight and Obese Adults
- Weight Management for Overweight Children and Adolescents
- Medical Nutrition, IFG/Type 2 Diabetes Prevention & Therapy
- Prevention & Delay of Type 2 Diabetes in Children and Adults with Impaired Fasting glucose (IFG) and/or Impaired Glucose Tolerance (IGT)
- Exercise for Type 2 Diabetes Prevention & Therapy
- Glycemic Control for Type 2 Diabetes in Children & Adults
- Oral agents for diabetes
- Lipid Treatment for Type 1 & Type 2 Diabetes in Adults
- Hypertension for Diabetes in Adults
- Insulin for Type 1 Diabetes in Children & Adults
- Insulin for Type 2 Diabetes in Children & Adults
- Initial Insulin Therapy for Type 2 Diabetes in Children and Adults: a Simplified Approach
- IV Insulin Infusion Protocol for Critically Ill Adult Patients in the ICU Setting
- ICU Insulin Orders – IV Insulin Infusion Protocol
- Orders for Adults with DKA and Hyperglycemic Hyperosmolar State (HHS)
- Transition From I.V. to S.Q. Insulin for Patients with Diabetes or Hyperglycemia
- Insulin Pump Therapy
- Macrovascular Risk Reduction: Antiplatelet Therapy
- Foot Care
  - Foot Screening Mapping Examples
  - Diabetic Foot Screen
  - Diabetic Foot Exam
  - Diabetic Foot Care/Referral
  - High Risk Scenario & Ulcer Management
- Recommendations for Treatment of Painful Peripheral Diabetic Neuropathy
- Care of the Elderly
  - Considerations for Elderly Persons with Diabetes
  - Guidelines for Management of the Elderly with Diabetes in Long-Term Care Facilities
  - Screening and Management of Hyperglycemia in the Geriatric Population

11. If you do not use any of the algorithms listed above, please explain or indicate what treatment algorithms you do use in your practice:

__________________________________________________________________________________________
__________________________________________________________________________________________

12. Please provide any additional feedback below:

__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________

Please return this form to:
Diabetes Program
Attn: Nurse Consultant
Texas Diabetes Program, Mail Code 1965
Dept. of State Health Services
P.O. Box 149347
Austin, TX 78714-9347
# Health Care Professional Education

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Overview</td>
<td>a. Introduction</td>
<td>1.1</td>
</tr>
<tr>
<td></td>
<td>b. Types of Diabetes</td>
<td>1.3</td>
</tr>
<tr>
<td></td>
<td>c. Facts about Diabetes</td>
<td>1.7</td>
</tr>
<tr>
<td></td>
<td>d. Pre-diabetes</td>
<td>1.13</td>
</tr>
<tr>
<td>2. Standards &amp; Practice Recommendations</td>
<td>a. Criteria for Diagnosing Diabetes</td>
<td>2.1</td>
</tr>
<tr>
<td></td>
<td>b. Diabetes Management Goals of Therapy</td>
<td>2.3</td>
</tr>
<tr>
<td></td>
<td>c. Diabetes Minimum Practice Recommendations</td>
<td>2.4</td>
</tr>
<tr>
<td></td>
<td>d. Recommended Adult Immunization Schedule</td>
<td>2.5</td>
</tr>
<tr>
<td>3. Pregnancy &amp; Diabetes</td>
<td>a. Gestational Diabetes (GDM) Standards of Care</td>
<td>3.1</td>
</tr>
<tr>
<td></td>
<td>b. Treatment of Gestational Diabetes</td>
<td>3.5</td>
</tr>
<tr>
<td></td>
<td>c. Pregestational Diabetes Guidelines</td>
<td>3.15</td>
</tr>
<tr>
<td>4. Monitoring</td>
<td>a. Self Monitoring Blood Glucose (SMBG)</td>
<td>4.1</td>
</tr>
<tr>
<td>5. Acute Complications of Diabetes</td>
<td>a. Hypoglycemia</td>
<td>5.1</td>
</tr>
<tr>
<td></td>
<td>b. Hyperglycemia</td>
<td>5.3</td>
</tr>
<tr>
<td></td>
<td>c. Vibrio vulnificus</td>
<td>5.5</td>
</tr>
<tr>
<td>7. Diabetes Education</td>
<td>a. Educating the Person with Diabetes</td>
<td>7.1</td>
</tr>
<tr>
<td></td>
<td>b. Teaching Strategies for Diverse Populations</td>
<td>7.3</td>
</tr>
<tr>
<td></td>
<td>c. National Standards for Diabetes Self-Management Education Programs</td>
<td>7.5</td>
</tr>
<tr>
<td>8. Medications</td>
<td>a. Diabetes Medications Supplement</td>
<td>8.1</td>
</tr>
<tr>
<td>9. Resources</td>
<td>a. Resources for Individuals with Diabetes</td>
<td>9.1</td>
</tr>
</tbody>
</table>
Introduction

The Texas Diabetes Council’s (TDC) Diabetes Tool Kit was prepared by an interdisciplinary team of volunteer certified diabetes educators (CDEs) and professional staff of the Texas Department of State Health Services Diabetes Prevention and Control Program to be of service to Texas practitioners, diabetes educators, and residents who live with diabetes. Many partners contributed to its development, revisions, and distribution.

The Tool Kit Features:

- Self-management training content based on the National Standards for Diabetes Education;
- Minimum Standards of Care and evidence-based treatment algorithms prepared by volunteer endocrinologists, physicians, nurses, dietitians, pharmacists, and professionals on the Medical Professionals Advisory Subcommittee of the Texas Diabetes Council.

This Tool Kit assists primary care providers, educators, and health plans to deliver quality care and to implement quality improvement efforts. The Tool Kit is a resource that includes professional and patient education materials.

Patient education materials in English and Spanish help primary care providers and educators address basic self-management education with their clients who have diabetes. These tools assist those who conduct diabetes self-management education, case management, or disease management.

Standards of Care

The Council’s Minimum Standards of Care for Diabetes in Texas are accompanied by decision support tools, i.e., a minimum practice recommendations flow sheet, treatment algorithms designed for primary care settings, and information intended for use in professional preparation and continuing education of licensed health care professionals and the medical leadership and case/disease management staff of health plans. The Kit promotes delivery of quality care and quality improvement efforts focused on provider practices and clinic or office systems. Charts and algorithms can be reproduced or integrated into the office’s medical record system to remind providers of critical preventive services and therapeutic targets and to set the basis for feedback on treatment strategies.

Diabetes Management

The Task Force on Community Preventive Services, a non-federal group supported by the Centers for Disease Control and Prevention, reviewed studies and concluded that diabetes disease management and case management can improve glycemic (blood sugar) control and physicians’ monitoring rates (A1c testing). Disease management includes identifying clients/members with diagnosed diabetes, implementing care plans that are proven to be effective, and tracking, measuring, and managing health outcomes.
Diabetes Self-Management Education

The Task Force also recommended self-management education for adults with type 2 diabetes in community settings, e.g., community centers, libraries, and places of worship.

Texas professionals may offer diabetes self-management training and information in clinical or community settings. The Council recognizes that most certified diabetes educators and programs credentialed by the American Diabetes Association (ADA) or Indian Health Services are located in metropolitan areas. Many patients receive information from various members of the diabetes care team: primary care physicians, nurses, pharmacists, dietitians, and specialists such as dentists, podiatrists, endocrinologists, and eye specialists. These health care providers may seek assistance with education and reinforcement from trained community health workers/promotores de salud, lay support group leaders, and county extension agents.

Updates

Updates to the algorithms in the Tool Kit will be available on the Internet at www.texasdiabetescouncil.org.

Acknowledgements

The Texas Diabetes Council thanks the volunteers on the Medical Professionals Advisory Subcommittee who developed the first edition of the Diabetes Tool Kit (2001) and oversaw its first significant revision (2003). The effort involved many diabetes professionals across Texas and was supported by organizations that consented to the inclusion of resource information in this reference.
What is Diabetes?

Diabetes is a serious chronic disease. It happens when too much glucose stays in the blood stream because there is either no insulin or not enough insulin that can move the glucose into the body’s cells. Most of the food people eat is changed into simpler proteins, fats, or a simple carbohydrate called glucose. Glucose is the form of sugar that cells need to make energy. The pancreas, a gland near the stomach, normally makes insulin to move glucose from the blood stream into the cells. In diabetes, the body cannot make insulin or properly use the insulin it has.

Controlling blood glucose helps to prevent the damage to blood vessels and nerves that lead to complications: blindness, amputations, kidney failure, stroke, heart attack, digestive and nerve problems, gum disease, and even depression (sadness). Good control is achieved by daily attention to nutrition, exercise, weight control, self-checks, and taking medicines as ordered. Regular checkups (including blood tests, dental exams, eye exams, and foot exams) are recommended.

TYPES OF DIABETES

There are 2 major types of diabetes. Several less common types of diabetes follow:

1. **Type 1 Diabetes**
   - Characterized by absolute insulin deficiency. This occurs as an autoimmune process destroys the pancreas’ ability to produce insulin.
   - The person with type 1 diabetes must inject insulin daily.
   - Onset occurs most often in childhood or adolescence, but can occur at any age.
   - Typical onset may be dramatic with polyuria, polydipsia, and polyphagia. Patients may report rapid weight loss regardless of their oral intake and poor energy/exercise tolerance.
   - If untreated, can progress to diabetic ketoacidosis (DKA) and coma.
   - Does not usually run in families, but there is a higher risk.
   - Usually occurs in normal-weight individuals.
   - Accounts for up to 10% of all diagnosed cases of diabetes.
   - Was called Insulin Dependent Diabetes (IDDM) or Juvenile Onset until 1997.

2. **Type 2 Diabetes**
   - Characterized by relative insulin deficiency. Type 2 diabetes is a progressive disease of insulin resistance in combination with insulin deficiency. The body may produce some insulin, but the body is unable to use it properly.
Gestational Diabetes Mellitus (GDM):  
- Characterized by any degree of glucose intolerance with onset or first recognition during pregnancy.
- Incidence - occurs in approximately 7% of all pregnancies, resulting in more than 135,000 cases in the United States annually. Prevalence may range from 1-14% of all pregnancies, depending on the population studied and diagnostic tests employed.
- Usually diagnosed between the 24th and 28th week of pregnancy.
- Treatment may include insulin and dietary changes. Medications are often discontinued in the post-partum period.
- Risk factors include:
  - Obesity
  - Maternal age
History of GDM with previous pregnancy
- Family history of diabetes
- Ethnicity — African American, Hispanic American, and American Indian origin
- Maternal hyperglycemia may result in increased maternal and fetal complications, including macrosomia, birth trauma, hypoglycemia, hypocalcemia, and jaundice. Rarely, fetal death may occur.
- Women with GDM have an increased risk of developing type 2 diabetes later in life. Staying physically active and achieving weight loss may help to prevent or delay type 2 diabetes.

Maturity Onset of Diabetes in Youth (MODY):
- A subtype of Type 2 diabetes occurring in individuals < 25 yrs of age (age of onset 15-25 yrs). A monogenic form that is inherited in a autosomal-dominant fashion (MODY 1-5).
- Characterized by a pure insulin secretory defect rather than an impairment of insulin sensitivity. Individuals secrete little insulin but require only small doses of exogenous insulin to control their glucose.
- Women with MODY often present with GDM

Latent Autoimmune Diabetes of Adulthood (LADA):
- Characterized by adult age at onset, the presence of diabetes associated autoantibodies (+ GAD and ICA), and delay from diagnosis in need for insulin therapy to manage hyperglycemia. Patients often have low to normal BMI, poor glycemic control in spite of adequate compliance to diet and oral agents, and decreasing body weight during a constant diet.
- Epidemiology of LADA is influenced by geography (more common in North America and Europe), genetic susceptibility, environmental factors, gender (males predominate), and age at diagnosis (30-60 yrs).
- A slowly progressive autoimmune diabetes, often mistaken for type 2 diabetes mellitus. LADA patients generally have more insulin secretory capacity than children with type 1, require less exogenous insulin for glucose control, and may have residual persistent c-peptide secretion.
- Treatment with oral agents fails relatively quickly. Patients progress to insulin dependence.

Other types:
- Steroid Induced Diabetes
- Cystic Fibrosis Related Diabetes
- Diabetes of the Elderly
- Diabetes in the HIV patient
- Other Medical Types of Diabetes- thalassemia, sp whipple procedure, etc.
Impaired Fasting Glucose* (IFG)
1. Fasting plasma glucose 100 mg/dL-125 mg/dL.

Impaired Glucose Tolerance* (IGT)
1. Two-hour plasma glucose 140 mg/dL-199 mg/dL. May have normal or near normal glycated hemoglobin (A1c) level.

Insulin Resistance
1. Condition in which blood glucose levels are held within non-diabetic ranges by rising insulin levels (2-3 times higher than normal).
2. Can progress to type 2 diabetes and increase cardiovascular risk in overweight people.
3. Conditions in which insulin resistance occurs:
   a. Type 2 diabetes
   b. Obesity, especially with central (abdominal) fat distribution with waist circumference > 40 inches (male), > 35 inches (female)
   c. Advanced maternal age
   d. Stress (major trauma, surgery, critical illness)
   e. Puberty: transient and developmentally normal reduced insulin sensitivity due to growth hormone
   f. Acanthosis nigricans (a skin marker seen in skin folds that indicates high insulin)
   g. Polycystic ovarian disease (PCOS) with accompanying hyperinsulinemia can occur in obese or non-obese females
   h. Hypertension (blood pressure > 140/90 mm Hg in adults)
   i. Dyslipidemia
4. Can be improved by weight loss (physical activity and dietary changes).

* Can be reversed in many obese people through weight reduction (at least 5-7%) by daily physical activity (30 minutes a day at least 5 days a week) and reduced-fat/calories nutrition.


Facts about Diabetes

A. Diabetes is a chronic disease. It affects daily life, most body systems, and is a family concern.

B. Diabetes affects 23.6 million adults (7.8%) in the United States, 6.2 million of whom do not yet know it.

C. Diabetes affects approximately 1.8 million Texans, and another 460,040 are at high risk of impaired glucose tolerance/insulin resistance.

D. Complications of diabetes in the United States:
   • Diabetes is the leading cause of kidney failure.
   • Diabetes is the leading cause of blindness among adults aged 20-74 years.
   • Diabetes causes mild to severe forms of nervous system damage in 60-70 percent of persons with diabetes.
   • Diabetes causes more than 60% of nontraumatic lower-limb amputations.
   • Diabetes causes more than 60% of nontraumatic lower-limb amputations.
   • Diabetes increases heart disease death rates among adults (2 to 4 times higher than adults without diabetes).
   • Diabetes increases stroke (2 to 4 times higher among people with diabetes)

E. Prevalence of diabetes by age groups:
   1. Age 60 or older — 23.1%
   2. Age 20 or older — 10.7%

F. Prevalence of diabetes by race/ethnicity in people 20 years or older:
   1. Non-Hispanic whites — 9.8%
   2. Non-Hispanic blacks — 14.7%
   3. Hispanic/Latino — 10.4% (2004-2006)
   4. American Indians and Alaska Natives — 16.5% (Indian Health Services) varies among tribes. Ranges from 6.0% (Alaska Natives) to 29.3% among American Indian adults in southern Arizona.

G. Direct and indirect costs of diabetes in the United States (2007) were almost $174 billion, including:
   1. $116 billion in direct costs (includes Medicaid and other state programs)
   2. $58 billion in indirect costs (lost wages and early death)

Source: CDC National Diabetes Fact Sheet, 2007
Texas Diabetes Fact Sheet, 2008

Survey estimates of diabetes prevalence rose from 8% in 2006 to 10.3% in 2007. The 2007 BRFSS survey had a substantially larger sample size than previous years; therefore, it may have provided a more accurate estimate of prevalence which is steadily increasing in the state and nation.

Prevalence estimates are based on surveys in which individuals are asked if they have been diagnosed with diabetes. Efforts to increase diabetes screening and awareness lead to more people knowing they have diabetes and, consequently, being able to report that they have been diagnosed. This increase in awareness would also be reflected in the estimated prevalence rate.

I. 2007 DIABETES PREVALENCE

Prevalence of Diagnosed\(^1\) Diabetes in Persons 18 and Older

An estimated 1.8 million persons aged eighteen years and older in Texas (10.3% of this age group) have been diagnosed with diabetes. Nationwide, 18.3 million persons eighteen years of age and older have been diagnosed with diabetes (9.0% of this age group).

Prevalence of Undiagnosed\(^2\) Diabetes in Persons 18 and Older

Another estimated 460,040 persons aged eighteen years and older in Texas are believed to have undiagnosed diabetes (based on 1999-2000 NHANES age-adjusted prevalence estimate of 2.5% of persons twenty years of age and older). The total for both diagnosed and undiagnosed diabetes is 2.2 million.

Prevalence of Diagnosed\(^1\) Diabetes by Sex in Persons 18 and Older

<table>
<thead>
<tr>
<th>Sex</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>853,751 (9.9%)</td>
</tr>
<tr>
<td>Female</td>
<td>942,698 (10.8%)</td>
</tr>
</tbody>
</table>

Prevalence of Diagnosed\(^1\) Diabetes by Race/Ethnicity in Persons 18 and Older

<table>
<thead>
<tr>
<th>Race/Ethnicity</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>White, non-Hispanic</td>
<td>751,235 (8.5%)</td>
</tr>
<tr>
<td>Black, non-Hispanic</td>
<td>244,590 (12.9%)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>721,779 (12.3%)</td>
</tr>
<tr>
<td>Other</td>
<td>88,524 (11.8%)</td>
</tr>
</tbody>
</table>
Prevalence of Diagnosed Diabetes by Race/Ethnicity and Age Group in Persons 18 and Older

<table>
<thead>
<tr>
<th>AGE GROUP</th>
<th>WHITE, NON-HISPANIC</th>
<th>BLACK, NON-HISPANIC</th>
<th>HISPANIC</th>
<th>OTHER</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-44</td>
<td>3.0%</td>
<td>3.7%</td>
<td>6.8%</td>
<td>3.8%</td>
</tr>
<tr>
<td>45-64</td>
<td>10.9%</td>
<td>17.6%</td>
<td>20.2%</td>
<td>21.1%</td>
</tr>
<tr>
<td>65+</td>
<td>17.5%</td>
<td>36.5%</td>
<td>34.4%</td>
<td>34.1%</td>
</tr>
<tr>
<td>Overall</td>
<td>8.5%</td>
<td>12.9%</td>
<td>12.3%</td>
<td>11.8%</td>
</tr>
</tbody>
</table>

**Sample size too small to report a reliable estimate (n<20).**

Prevalence of Diagnosed Diabetes by Age Group in Persons 18 and Older

- 18-29 Years: 2.7%
- 30-44 Years: 5.5%
- 45-64 Years: 14.5%
- 65+: 23.2%

Prevalence of Diagnosed Diabetes by Educational Level in Persons 18 and Older

- No High School Diploma: 15.8%
- High School Graduate: 11.3%
- Some College: 10.0%
- College+: 6.9%

II. DIABETES MORTALITY

Deaths Among Persons with Diabetes

Diabetes was the sixth leading cause of death in Texas 2002 through 2005. In 2005, 5,593 deaths were directly attributed to diabetes. Diabetes was also the sixth leading cause of death nationally 2002 through 2004, and seventh in 2005. Diabetes is believed to be under-reported on death certificates in Texas and the nation, both as a condition and as a cause of death.
The map above shows the age-adjusted mortality rates per 100,000 persons for Texas by county for the years 2002 through 2005, with diabetes as the underlying cause of death. The state rate for the four years is 31.1 per 100,000. More of the counties in Health Service Regions 8 and 11 fall into the “significantly higher than state rate” and “higher than state rate, but not significantly different” categories. Many counties along the eastern part of our state fall into the “higher than state rate, but not significantly different” category.

**Diabetes Mortality Rate (Per 100,000) by Race/Ethnicity, Texas, 2005**

The 2005 diabetes mortality rate for Texas was 30 deaths per 100,000 persons. Mortality rates for each race/ethnicity were applied to the 2005 population by race/ethnicity:

**Of persons who have diabetes, in 2004:**

- 21 per 100,000 whites (non-Hispanic)
- 52 per 100,000 Hispanics
- 55 per 100,000 blacks (non-Hispanic)
- 15 per 100,000 persons who fall in the “Other” category

The 2005 mortality rates (per 100,000) for blacks (non-Hispanic) and Hispanics were more than double that of whites (non-Hispanic).
III. DIABETES IN PERSONS LESS THAN 18 YEARS OF AGE

Diabetes in childhood is mainly type 1, an autoimmune disorder that destroys insulin-producing cells, requiring multiple daily insulin injections or a pump. About one in every 400 to 600 Texas children and adolescents has type 1 diabetes. It is the second most prevalent chronic disease of childhood (after asthma).

It is important to note that the incidence of type 2 diabetes in persons less than 18 years of age has been increasing in recent years. However, representative data that would be needed to monitor diabetes trends in youth by type are not available for Texas or the nation.

1 Source: 2007 Texas Behavioral Risk Factor Surveillance System, Statewide BRFSS Survey, for persons who are eighteen years of age and older. Data include both type 1 and type 2 diabetes. Persons with diabetes include those who report that they have been told by a doctor that they have diabetes. Women who report diabetes only during pregnancy are not included in prevalence. Prevalence data for 2008 will be available in fall of 2009 (Prevalence data are available for the year prior to the current year).


3 Texas Department of State Health Services, Texas Vital Statistics. Data include male and female, and all ages. Data are provisional.
Pre-diabetes

Definitions: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have been officially termed “pre-diabetes.” The term is used with patients who have higher than normal blood glucose levels (IFG) or insulin resistance (IGT) but not at diagnostic levels. Most people with pre-diabetes are statistically likely to develop type 2 diabetes within 10 years of assessment.

Similarly, women who experience gestational diabetes are also at high risk for developing type 2 diabetes in later years (a 20-50% chance of developing diabetes within 5-10 years). Source: CDC.

Research findings: The Diabetes Prevention Program (DPP) reported in Diabetes Care, April 2002, established that overweight people with impaired glucose tolerance could delay or prevent the onset of type 2 diabetes over the three-year study course with modest lifestyle changes, namely regular physical activity and dietary changes. Metformin, used in one arm of the study, was found to contribute to reducing the risk of type 2 diabetes among younger (25-40 years old) and heavier (50-80 pounds overweight) subjects.

Screening and making recommendations to manage pre-diabetes should be a priority for all health care providers and considered at any health care visit.

Co-morbidity: Pre-diabetes is not just an early warning for type 2 diabetes. Persons with IFG and IGT have a higher risk of cardiovascular disease. This risk is constant even if they do not develop type 2 diabetes, thus, they warrant evaluation and intervention for other cardiovascular risk factors, usually hypertension and dyslipidemia.

Diagnostic guidelines: Diagnosis of IGT is preferably done by the 2-hour oral glucose tolerance test (OGTT) using 75-gram glucose solution after an 8- to 12-hour fast. OGTT is more likely to identify insulin resistance while fasting plasma glucose (FPG) can detect limited insulin secretion. Impaired Fasting Glucose: Fasting plasma glucose = 100 mg/dL-125 mg/dL.

Impaired Glucose Tolerance: Oral glucose tolerance test value is 140 mg/dL-199 mg/dL. May have normal or near normal A1c level.

Treatment guidelines: Type 2 diabetes prevention or delay among persons at high risk (pre-diabetes) involves modest weight loss (5 to 7% of total body weight) through diet changes to reduce calories and moderate exercise (30 minutes a day, at least 5 days a week) to burn calories.

Concomitant risk for CVD and stroke should be addressed. Evaluate and aggressively treat hypertension and/or dyslipidemia and counsel patients who smoke to quit.
• **See Weight Loss Algorithm:**
  Weight Management for Overweight Children and Adolescents

• **See Weight Loss Algorithm:**
  Weight Loss for Overweight and Obese Adults

• **See Exercise Algorithm:**
  Exercise for Type 2 Diabetes Prevention and Therapy

• **See Prevention Algorithm:**
  Prevention and Delay of Type 2 Diabetes in Children and Adults with Impaired Fasting Glucose (IFG) and/or Impaired Glucose Tolerance (IGT)
Criteria for Diagnosing Diabetes

A. Fasting plasma glucose (FPG) ≥ 126 mg/dL
   or
B. Symptoms of hyperglycemia and a casual plasma glucose ≥ 200 mg/dL
   or
C. 2-hour plasma glucose ≥ 200 mg/dL during an OGTT.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Fasting Plasma Glucose (FPG) (Preferred)*</th>
<th>Casual Plasma Glucose (11.1 mmol/l) plus symptoms)**</th>
<th>Oral Glucose Tolerance Test (OGTT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>FPG ≥ 126 mg/dL (7.0 mmol/l)**</td>
<td>FPG ≥ 200 mg/dL (11.1 mmol/l) plus symptoms)*****</td>
<td>Two-hour Plasma Glucose 2hPG ≥ 200 mg/dL****</td>
</tr>
<tr>
<td>Impaired Glucose Homeostasis (Pre-Diabetes)</td>
<td>Impaired Fasting Glucose (IFG) IFG = FPG 100-125 mg/dL</td>
<td>Impaired Glucose Tolerance (IGT) = 2hPG 140-199 mg/dL</td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>FPG &lt; 100 mg/dL</td>
<td>2hPG &lt; 140 mg/dL</td>
<td></td>
</tr>
</tbody>
</table>

* The FPG is the preferred test for diagnosis in children and nonpregnant adults, but any one of the three listed is acceptable. In the absence of unequivocal hyperglycemia with acute metabolic decompensation, one of these three tests should be used on a different day to confirm diagnosis.

** Fasting is defined as no caloric intake for at least 8 hours.

*** Casual is any time of day without regard to time since last meal. Symptoms are polyuria, polydipsia, and unexplained weight loss.

**** OGTT should be performed using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water. The OGTT is not recommended for routine clinical use.

Source: Diabetes Care, Vol. 31, (Suppl 1), January 2008
# Diabetes Management Goals of Therapy

## Goals for Non-Pregnant Diabetic Patients

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Goal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood Sugar Before Meals</td>
<td>70-130 mg/dL (normal: &lt; 100 mg/dL)*</td>
</tr>
<tr>
<td></td>
<td>&lt; 110 mg/dL**</td>
</tr>
<tr>
<td>Blood Sugar 2 hrs. After Meals</td>
<td>&lt; 180 mg/dL* (peak)</td>
</tr>
<tr>
<td></td>
<td>&lt; 140 mg/dL**</td>
</tr>
<tr>
<td>Blood Sugar at Bedtime</td>
<td>110-150 mg/dL* (normal &lt; 110 mg/dL)</td>
</tr>
<tr>
<td>Blood Sugar at 3:30 a.m.</td>
<td>goal = 100 mg/dL*</td>
</tr>
<tr>
<td>Blood Sugar Before Exercising</td>
<td>100 mg/dL*</td>
</tr>
<tr>
<td></td>
<td>If &lt; 100 mg/dL, snack before exercising (one carb [15 g] for every 30 minutes).</td>
</tr>
<tr>
<td></td>
<td>If type 1 diabetes with blood sugar &gt; 250 mg/dL, caution against exercise, check ketones, drink water, and notify doctor (may need to increase insulin).</td>
</tr>
<tr>
<td>A1c</td>
<td>≤ 6.5%**, ***</td>
</tr>
<tr>
<td>Ketones</td>
<td>Negative</td>
</tr>
<tr>
<td>Blood Pressure</td>
<td>≤ 130/80 mmHg; if ≥ 1 g proteinuria, ≤ 125/75 mmHg</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>&lt; 150 mg/dL</td>
</tr>
<tr>
<td>LDL-Cholesterol</td>
<td>&lt; 100 mg/dL</td>
</tr>
<tr>
<td>HDL-Cholesterol</td>
<td>≥ 40 mg/dL</td>
</tr>
<tr>
<td>Microalbuminuria</td>
<td>&lt; 30 mg/24 hour</td>
</tr>
<tr>
<td>eGFR</td>
<td>≥ 60 **</td>
</tr>
<tr>
<td>Body Mass Index (BMI)</td>
<td>&lt; 25 (Overweight 25-29.9; Obesity ≥ 30)</td>
</tr>
</tbody>
</table>

** American Association of Clinical Endocrinologists (AACE), Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus. Endocrine Practice, Vol. 13 (Suppl 1), May/June 2007
*** AACE (2007) and the Texas Diabetes Council (2008).
# Diabetes Minimum Practice Recommendations

| Exam/Test/Counseling | Schedule | Suggested Result Codes: 
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>G=Ordered, N=Normal, A=Abnormal, E=Done Elsewhere, R=Referred</td>
</tr>
<tr>
<td><strong>INITIAL VISIT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Complete history &amp; physical</td>
<td>Initial visit and at clinician’s discretion (including risk factors, exercise &amp; diet)</td>
<td>Date Result</td>
</tr>
<tr>
<td>2. Diabetes Education</td>
<td>Initial visit and at clinician’s discretion</td>
<td>Date Result</td>
</tr>
<tr>
<td>3. Medical Nutrition Therapy</td>
<td>Initial visit and at clinician’s discretion</td>
<td>Date Result</td>
</tr>
<tr>
<td>4. Exercise Counseling</td>
<td>Initial visit and at clinician’s discretion</td>
<td>Date Result</td>
</tr>
<tr>
<td>5. Psychosocial Counseling</td>
<td>Initial visit and at clinician’s discretion</td>
<td>Date Result</td>
</tr>
<tr>
<td>6. Lifestyle/Behavior Changes Counseling</td>
<td>Initial visit and at clinician’s discretion</td>
<td>Date Result</td>
</tr>
<tr>
<td><strong>EVERY VISIT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Weight/Height/BMI</td>
<td>Every Visit</td>
<td>Date Result</td>
</tr>
<tr>
<td>Adult Overweight=BMI 25–29.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adult Obesity=BMI≥30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Blood Pressure</td>
<td>Every Visit</td>
<td>Date Result</td>
</tr>
<tr>
<td>Target: &lt;130/80 mm Hg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target: &lt;125/75 mm Hg if ≥1 g proteinuria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Foot Inspection</td>
<td>Every Visit</td>
<td>Date Result</td>
</tr>
<tr>
<td>Visual inspection for skin and nail lesions, calluses, infections</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ANNUALLY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Oral/Dental Inspection</td>
<td>Refer for dental care annually or as needed</td>
<td>Date Result</td>
</tr>
<tr>
<td>11. Growth and Development (including height) in Children</td>
<td>Every Visit</td>
<td>Date Result</td>
</tr>
<tr>
<td>12. Aspirin/Antiplatelet Prophylaxis (if no contraindications)</td>
<td>Every Visit</td>
<td>Date Result</td>
</tr>
<tr>
<td>Type 1 or 2 ≥ age 30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. A1c</td>
<td>Every 3–6 months</td>
<td>Date Result</td>
</tr>
<tr>
<td>Individualize goal based on patient risk factors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intensive management - A1c &lt; 6-7%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less intensive management - A1c &lt; 7-8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14. Kidney evaluation</td>
<td>Type 1: Annually beginning 5 years from diagnosis Type 2: Initial, then annually</td>
<td>Date Result</td>
</tr>
<tr>
<td>Estimate GFR (eGFR) &amp; microalbumin determination (≥30mg = abnormal). Consider nephro/endocrine evaluation at Stage 3 (eGFR &lt;60); also consider PTH &amp; Hgb if CKD Stage 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>If significant proteinuria, monitor serum creatinine every 3–6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15. Dilated funduscopic eye exam</td>
<td>Type 1: Annually beginning 5 years from diagnosis Type 2: Initial, then annually</td>
<td>Date Result</td>
</tr>
<tr>
<td>By an ophthalmologist or therapeutic optometrist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16. Oral/Dental Exam</td>
<td>Annually or as needed</td>
<td>Date Result</td>
</tr>
<tr>
<td>Refer to appropriate provider</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17. Foot Exam</td>
<td>Annually or as needed</td>
<td>Date Result</td>
</tr>
<tr>
<td>Complete foot exam and neurologic assessment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18. Lipid Profile</td>
<td>Annually if at goal; otherwise every 3–6 months (&gt; age 18)</td>
<td>Date Result</td>
</tr>
<tr>
<td>Targets: LDL-C &lt;100 mg/dL (CHD &lt;70mg/dL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglycerides &lt;150 mg/dL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19. Immunizations</td>
<td>Annually Every 10 Years</td>
<td>Date Result</td>
</tr>
<tr>
<td>Influenza (Flu) Vaccine</td>
<td>Initial; repeat per ACIP</td>
<td></td>
</tr>
<tr>
<td>Td Vaccine</td>
<td>Per CDC Schedule</td>
<td></td>
</tr>
<tr>
<td>Pneumococcal Vaccine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Childhood Immunizations</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Diabetes Minimum Practice Recommendations**

See website (http://www.texasdiabetescouncil.org) for latest version and disclaimer.

1. *Diabetes Education should address the following:* self-management skills (i.e. monitoring, sick day management), medications, frequency of hypoglycemia, high-risk behaviors (e.g. smoking, alcohol), adherence with self-care (self-management plan from the last visit including diet, medication use, exercise plan), assessment of complications, diabetes knowledge and follow-up of referrals.


3. *Less intensive management if:* Evidence of advanced or poorly controlled cardiovascular and/or microvascular complications, hypoglycemia unawareness, vulnerable patient (e.g. impaired cognition, dementia, fall history).
## Recommended Adult Immunization Schedule

### UNITED STATES - 2009

Note: These recommendations should be read with the footnotes that follow containing number of doses, intervals between doses, and other important information.

### Figure 1. Recommended adult immunization schedule, by vaccine and age group

<table>
<thead>
<tr>
<th>VACCINE</th>
<th>AGE GROUP</th>
<th>19-26 years</th>
<th>27-49 years</th>
<th>50-59 years</th>
<th>60-64 years</th>
<th>&gt;65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetanus, diphtheria, pertussis (Td/Tdap)</td>
<td>Substitute 1-time dose of Tdap for Td booster; then boost with Td every 10 yrs</td>
<td>Td booster every 10 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus (HPV)</td>
<td>2 doses (females)</td>
<td>2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zoster</td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella (MMR)</td>
<td>1 or 2 doses</td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td>1 dose annually</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal (polysaccharide)</td>
<td>1 or 2 doses</td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>3 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal</td>
<td>1 or more doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Covered by the Vaccine Injury Compensation Program.

For all persons in this category who meet the age requirements and who lack evidence of immunity (e.g., lack documentation of vaccination or have no evidence of prior infection).

Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications).

No recommendation.

---

### Figure 2. Vaccines that might be indicated for adults based on medical and other indications

<table>
<thead>
<tr>
<th>VACCINE</th>
<th>INDICATION</th>
<th>Pregnancy</th>
<th>Immune compromising conditions (including human immunodeficiency virus [HIV])</th>
<th>CD4+ T lymphocyte count &lt;200 cells/µL</th>
<th>HIV infection, 10-18 years</th>
<th>Diabetes, heart disease, chronic lung disease, chronic renal disease, chronic liver disease</th>
<th>Kidney failure, end-stage renal disease, receipt of hemodialysis</th>
<th>Health-care personnel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetanus, diphtheria, pertussis (Td/Tdap)</td>
<td>Td</td>
<td>Substitute 1-time dose of Tdap for Td booster; then boost with Td every 10 yrs</td>
<td>Td booster every 10 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus (HPV)</td>
<td>3 doses for females through age 26 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zoster</td>
<td>Contraindicated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella (MMR)</td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td>1 dose TIV annually</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal (polysaccharide)</td>
<td>1 or 2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>3 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal</td>
<td>1 or more doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly indicated for adults ages 19 years and older, as of January 1, 2009. Licensed combination vaccines may be used whenever any components of the combination are indicated and when the vaccine's other components are not contraindicated. For detailed recommendations on all vaccines, including those used primarily for travelers or that are issued during the year, consult the manufacturers' package inserts and the complete statements from the Advisory Committee on Immunization Practices (ACIP), the American Academy of Family Physicians (AAFP), the American College of Obstetricians and Gynecologists (ACOG), and the American College of Physicians (ACP).

Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System (VAERS). Reporting forms and instructions on filing a VAERS report are available at www.vaers.hhs.gov or by telephone, 800-CDC-INFO (800-232-4636) in English and Spanish, 24 hours a day, 7 days a week.

Information on how to file a Vaccine Injury Compensation Program claim is available at www.hrsa.gov/vaccinecompensation or by telephone, 800-338-2382. To file a claim for vaccine injury, contact the U.S. Court of Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005; telephone, 202-357-6400.

Additional information about the vaccines in this schedule, extent of available data, and contraindications for vaccination is also available at www.cdc.gov/vaccines or from the CDC-INFO Contact Center at 800-311-3435 (in English and Spanish), 24 hours a day, 7 days a week. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

---

STANDARDS AND PRACTICE RECOMMENDATIONS 2.5
Footnotes

Recommended Adult Immunization Schedule—UNITED STATES—2008

For complete recommendations by the Advisory Committee on Immunization Practices (ACIP), visit www.cdc.gov/vaccines/recs/acip-latest.htm.

1. Tetanus, diphtheria, and acellular pertussis (Tdap) vaccination

Tdap should replace a single dose of Td for adults aged 10 through 64 years who have not received a dose of Tdap previously.

- Adults with uncorrected or incomplete history of primary vaccination series with tetanus and diphtheria toxoids and pertussis vaccine, and any doses of tetanus toxoid given after the primary series should receive 1 dose of Tdap. A primary series for adults is 3 doses of tetanus and diphtheria toxoids-containing vaccines; administer the first 2 doses at least 4 weeks apart and the third dose 12 months after the second. Tdap can substitute for a previous primary series or a booster dose of tetanus toxoid vaccine given at the end of pregnancy if it is not given at that time.

- If a woman is pregnant and received the last Td vaccination 10 or more years previously, administer Td during the second or third trimester. If the woman received the last Td vaccination less than 10 years previously, administer Tdap during the immediate postpartum period. A dose of Tdap is recommended for postpartum women, close contacts of infants aged less than 12 months, and all health-care personnel with direct patient contact if they have not previously received Tdap. An interval as short as 2 to 3 years from the last Td vaccine should be considered for persons exposed to tetanus or pertussis. Tdap may be administered simultaneously with Tdap administered in the immediate postpartum period, or Tdap may be administered instead of Td a pregnant woman after an interviewed discussion with the patient.

Consult the ACIP statement for recommendations for administering Td as prophylaxis in wound management.

2. Human papillomavirus (HPV) vaccination

- HPV vaccine should be administered to females aged 9 through 26 years (and may begin at 9 years) who have not completed the full vaccine series. History of genital warts, abnormal Pap test results, or human papillomavirus (HPV) infection does not exclude HPV vaccination. HPV vaccination is recommended for persons with such histories.

- Ideally, vaccine should be administered before potential exposure to HPV through sexual activity; however, females who are sexually active should still benefit from vaccination consistent with other recommended indications. Sexually active females who have not been infected with any of the four HPV types contained in the vaccine are the primary target of the vaccine. Vaccination is also beneficial for females who have already been infected with one or more of the HPV vaccine types.

- The series consists of 3 doses. The second dose should be administered 2 months after the first dose, the third dose should be administered 6 months after the first dose.

- During adolescence, females should be specifically recommended for females with the medical indications described in Figure 2. ‘Vaccines that might be indicated for adults based on medical and other indications.’ Because HPV vaccine is not a live-virus vaccine, it may be administered to persons with the medical indications described in Figure 1, however, the immune response and vaccine efficacy might be less for persons with the medical indications described in Figure 2 than in persons who do not have the medical indications described or who are immunocompromised. Health-care providers who have been vaccinated against HPV should not administer HPV vaccine to persons with such histories.

3. Varicella vaccination

- If a person had varicella infection or has not otherwise received varicella vaccine, varicella immune status cannot be determined with certainty. Special consideration should be given to those for whom 1) close contact with persons with varicella is at high risk for severe disease (e.g., health-care personnel and family contacts of persons with immunocompromising conditions); or 2) are at high risk for exposure or transmission (e.g., employees, residents, or visitors in institutional settings, including correctional institutions; college students; military personnel; and adults living in households with young children). However, studies suggest good immunogenicity in persons who have sickle cell disease, sickle cell trait, and thalassemia trait. Special consideration should be given to those who 1) have a history of varicella; 2) have someone in the household with a weak immune system (e.g., congenital or acquired immunodeficiency); 3) are members of the military; 4) have contact with Immunocompromised persons (e.g., children aged <5 years, residents of long-term care facilities, and persons with HIV infection); 5) are health-care workers; 6) have other high-risk medical conditions (e.g., diabetes, chronic lung disease, or renal failure); and 7) have a parent or other close contact who might have been exposed. Varicella vaccination may be considered for persons 3 through 11 years of age with moderate to severe immunodeficiency.

- A single dose of varicella vaccine should be given to active duty personnel deployed in regions where varicella is endemic. Inactivated vaccines generally are acceptable (e.g., pneumococcal, meningococcal, and influenza vaccines) for persons who are in high-risk settings.

4. Hepatitis A vaccination

- Single-antigen varicella vaccine formulations should be administered in 2-dose schedule at either 0 and 4–6 months (Havrix®), or 0 and 8–12 months (Varivax®). If the combined hepatitis A and hepatitis B vaccine (VacciNaMe™) is used, administer 3 doses at 0, 1, and 6 months; alternatively, 4-dose schedule administered on days 0, 1, and 21 or 30 followed by a booster dose at month 12 may be used.

- All adults born before 1957 generally are considered immune to measles.

- Ideally, vaccine should be administered before potential exposure to HPV through sexual activity; however, females who are sexually active should still benefit from vaccination consistent with other recommended indications. Sexually active females who have not been infected with any of the four HPV types contained in the vaccine are the primary target of the vaccine. Vaccination is also beneficial for females who have already been infected with one or more of the HPV vaccine types.

- The series consists of 3 doses. The second dose should be administered 2 months after the first dose, the third dose should be administered 6 months after the first dose.

- During adolescence, females should be specifically recommended for females with the medical indications described in Figure 2. ‘Vaccines that might be indicated for adults based on medical and other indications.’ Because HPV vaccine is not a live-virus vaccine, it may be administered to persons with the medical indications described in Figure 1, however, the immune response and vaccine efficacy might be less for persons with the medical indications described in Figure 2 than in persons who do not have the medical indications described or who are immunocompromised. Health-care providers who have been vaccinated against HPV should not administer HPV vaccine to persons with such histories.

5. Measles, mumps, rubella (MMR) vaccination

- Adults born before 1960 generally are considered immune to mumps. Adults born during or after 1960 should receive 1 or more doses of MMR unless they have a medical contraindication, documentation of 1 or more dose, history of measles based on health-care provider diagnosis, or laboratory evidence of immunity.

- A second dose of MMR is recommended for adults who 1) have recently received measles or mumps vaccine or have been exposed to mumps or are at an increased age group; 2) are students in postsecondary educational institutions; 3) work in a health-care facility; or 4) plan to travel internationally. A complete series consists of 3 doses. The second dose should be administered 2 months after the first dose.

- A single dose of zoster vaccine is recommended for adults aged 60 years and older regardless of whether they have received a prior dose of herpes zoster. Persons with chronic medical conditions may be vaccinated unless their condition constitutes a contraindication.

6. Influenza vaccination

- Adult patients receiving hemophilia or with other immunocompromising conditions, 4 doses of 40 μg/mL, (Recombinant [r]H5N1) administered as a 2-dose schedule or 2 doses of 20 μg/mL (Engerix® [r]) administered simultaneously on a 4-dose schedule at 0, 1, and 6 months.

- Meningoococcal vaccination

- Vaccination is recommended for adults whose contact with the preceding indicators who are aged 25 years or younger, although mumps vaccination schedule for older adults is not recommended for adults previously vaccinated with MPSV who remain at increased risk for infection (e.g., persons residing in areas in which the disease is endemic).

- Select conditions for which Haemophilus influenzae type b (Hib) vaccine may be used

Hib vaccine generally is not recommended for persons aged 5 years and older. Hib vaccine efficacy data are available on which to base a recommendation concerning use of Hib vaccine for older children and adults. However, studies suggest good immunogenicity in persons who have sickle cell disease, leukemia, or HIV infection or who have a febrile illness; administering 1 dose of vaccine to these persons is not contraindicated.

- 12. Selected conditions for which Haemophilus influenzae type b (Hib) vaccine may be used

Hib vaccine generally is not recommended for persons aged 5 years and older. Hib vaccine efficacy data are available on which to base a recommendation concerning use of Hib vaccine for older children and adults. However, studies suggest good immunogenicity in persons who have sickle cell disease, leukemia, or HIV infection or who have a febrile illness; administering 1 dose of vaccine to these persons is not contraindicated.

- 13. Immunocompromising conditions

- Vaccinated adults generally are acceptable (e.g., pneumococcal, meningococcal, and influenza [trivalent inactivated influenza vaccine]); and live vaccines generally are avoided in persons with immune deficiencies or immunocompromising conditions. Information on specific conditions is available at www.cdc.gov/vaccines/recs/acip-latest.htm.

- STANDARDS AND PRACTICE RECOMMENDATIONS
Gestational Diabetes (GDM) defined as “glucose intolerance with onset or first recognition during pregnancy.”

I. Who to Screen (Universal screening is suggested)

1. Those at High Risk for GDM

The following pregnant women are at high risk for developing GDM:

- Member of an ethnic group with a higher than normal rate of type 2 diabetes
- Glycosuria at the first prenatal visit
- Polycystic ovary syndrome
- A family history of diabetes, especially in first degree relatives
- Prepregnancy weight 110 percent of ideal body weight or significant weight gain in early adulthood
- Age greater than 25 years
- Previous delivery of a baby greater than 9 pounds (4.1 kg)
- Personal history of abnormal glucose tolerance
- Previous unexplained perinatal loss or birth of a malformed child
- Maternal birth weight greater than 9 pounds (4.1 kg) or less than 6 pounds (2.7 kg)
- Current use of glucocorticoids
- Personal birth weight of over 9 lbs


2. Those at Low Risk for GDM

Although, there is little agreement regarding who should be screened between American College of Obstetricians and Gynecologists (ACOG) and ADA, Jovonovic (2006) suggests universal screening since identifying pregnant women with hyperglycemia has proven to improve outcomes. Jovonovic and ACOG believe that universal screening is more practical and that selective screening is not sensitive enough.

ACOG and ADA suggested that screening may be omitted in low risk women. Such women must have all of the following characteristics:

- Age less than 25 years
- Normal weight before pregnancy
Member of an ethnic group with a low prevalence of GDM (i.e., patient is NOT Hispanic, African, Native American, South or East Asian, Pacific Islander)

No first degree relative with diabetes mellitus

No history of abnormal glucose tolerance

No history of poor obstetric outcome

(Diabetes Care, 2004; ACOG, 1994 & 2001).

II. Guidelines for Screening

1. Screen pregnant women at first prenatal visit if undiagnosed type 2 diabetes is suspected and/or the following characterize the pregnant woman:
   - Marked obesity
   - Personal history of GDM [33 to 50 percent risk of recurrence, and some of these recurrences may represent unrecognized type 2 diabetes (ACOG, 2001)]
   - Glycosuria
   - Strong family history of diabetes

2. Screening is optimally performed at 24 to 28 weeks of gestation (Jovonovic & Peterson, 1985).

3. Further screening unnecessary in the following scenario that is diagnostic of diabetes if confirmed on a subsequent day:
   - Evaluation of any woman who has a random serum glucose value ≥ 200 (11.1 mmol/L)
   - Fasting serum glucose value ≥ 126 (7.0 mmol/L) is unnecessary, because these findings alone are diagnostic of diabetes, if confirmed on a subsequent day (Diabetes Care Suppl, 2004)

III. Tests for Screening

Note: 50-g oral glucose challenge test is suggested with ≥ 130 as threshold for abnormal test

50-g oral glucose challenge test for screening (without regard to timing of last meal) is done, followed by serum glucose measurement one hour later:

Abnormal Finding is as follows:
   - Value 130 to 140 (7.8 mmol/L). Jovonovic (2006) uses 130 as the threshold for outpatients. Avoid the use of capillary blood for testing.

Sensitivity of values:
   - At the 130 threshold, the test is positive in 20 to 25 percent of pregnant women and detects 90 percent of gestational diabetics.
   - At the 140 threshold, 14 to 18 percent of tests will screen positive and 80 percent of gestational diabetics will be detected (Brody, et al., 2003). ACOG and the ADA have stated that either threshold may be used.
Women with an abnormal value are then given a 100-g, three hour oral glucose tolerance test (GTT).

Universal screening using a threshold serum glucose concentration of 130 (7.2 mmol/L) had 100 percent sensitivity, but 25 percent of women screened required a GTT and the cost per case diagnosed was $249 (ACOG, 2004). Raising the serum glucose threshold value to 140 (7.8 mmol/L) dropped the sensitivity to 90 percent with 15 percent of women screened requiring a GTT. In this protocol, the cost per case diagnosed was $222.

According to Jovonovic (2006) an A1c higher than 6.5 percent suggests diabetes, but A1c below this level should not be taken as evidence against the diagnosis of diabetes.

**IV. Diagnostic Testing for Women that Screen Positive**

- A three hour oral GTT for definitive diagnosis is warranted
- In populations/patients at very high risk of GDM, obtaining a GTT without performing a prior screening test (glucose challenge test) may be cost-effective

GDM is present if two or more of the following serum glucose values are met or exceeded:

- Fasting serum glucose concentration ≥95 (5.3 mmol/L)
- One-hour serum glucose concentration ≥180 (10 mmol/L)
- Two-hour serum glucose concentration ≥155 (8.6 mmol/L)
- Three-hour serum glucose concentration ≥140 (7.8 mmol/L)
- Carbohydrate loading for three days has been recommended before the GTT, but is probably not necessary

(Fourth International Workshop-Conference on Gestational Diabetes)

The Fourth International Workshop-Conference on Gestational Diabetes GTT values cited above are based upon the Carpenter and Coustan modification of earlier values (Carpenter and Coustan, 1982).

They are lower than those proposed by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus and the National Diabetes Data Group (NDDG), (Diabetes Care, Suppl, 2000). The values are lower because the thresholds derived from the older Somogyi-Nelson method of glucose analysis were corrected to account for the enzymatic assays currently in use. (See following table.)

<table>
<thead>
<tr>
<th>Status</th>
<th>Plasma or Serum Glucose Level Carpenter/Coustan Conversion mg/dL/ mmol/L</th>
<th>Plasma Level National Diabetes Data Group Conversion/mmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting</td>
<td>95 mg/dL/ 5.3 mmol/L</td>
<td>105 mg/dL/ 5.8 mmol/L</td>
</tr>
<tr>
<td>One Hour</td>
<td>180 mg/dL/ 10 mmol/L</td>
<td>190 mg/dL/ 10.6 mmol/L</td>
</tr>
<tr>
<td>Two Hours</td>
<td>155 mg/dL/ 8.6 mmol/L</td>
<td>165 mg/dL/ 9.2 mmol/L</td>
</tr>
<tr>
<td>Three Hours</td>
<td>140 mg/dL/ 7.8 mmol/L</td>
<td>145 mg/dL/ 8.0 mmol/L</td>
</tr>
</tbody>
</table>
Thus, application of the more stringent Fourth International Workshop criteria to all women with positive screening test results reduced the prevalence of infants weighing < 4000 grams from 17.1 to 16.9 percent, and the prevalence of infants weighing < 4500 grams from 3.0 to 2.9 percent.

ACOG considers use of either the Fourth International Workshop or the National Diabetes Data Group criteria acceptable for diagnosis of GDM. The ADA recommends use of the Fourth International Workshop-Conference on Gestational Diabetes criteria.

Treating women with one abnormal GTT value decreases the risk of a macrosomic infant and is cost-effective. These women often have insulin resistance along with fasting insulin levels similar to women with GDM.

There is not complete agreement on treatment of women with abnormal GTT.

- Some treat them as GDM would be treated if GDM criteria is met
- Some wait and consider further intervention following repeated oral GTT in four weeks

Jovonovic and others consider use of:

- Two-hour 75-g GTT often more cost-effective than the three-hour test
- The ADA and World Health Organization (WHO) have endorsed use of the two-hour 75-g oral GTT for diagnosis of GDM
- Criteria for diagnosis vary:
  - Some use test as a one step approach for both screening and diagnosis, no benefits drawn

Other tests that should be considered:

- GDM confirmed with abnormal GTT (ADA)
- Serum glucose concentration that is > 140 (7.8 mmol/L) after the 50-g glucose challenge is associated with a 25 to 30 percent risk of a macrosomic infant if no treatment is offered (Jovonovic & Peterson, 1985)
- Fasting serum glucose concentration > 90 (5 mmol/L) at 24 to 28 weeks of gestation, and
- A1c value above normal, are highly sensitive and a specific predictor of subsequent infant macrosomia in the general obstetrical population (Schrader, et al., 1995). Hemoglobin values alone were not sufficiently sensitive to predict those women at risk of delivering a macrosomic infant.

The ADA will not re-address the criteria for screening and diagnosis until the results of the National Institutes of Health sponsored Hyperglycemia and Adverse Pregnancy (HAPO) Clinical Trial is complete in 2007.
Treatment of Gestational Diabetes

I. Medical Nutrition Therapy (MNT)

MNT Recommended in the following situations:

- Those who do not meet GDM criteria, but have fasting blood glucose > 90
- Abnormal glucose challenge test
- Or one abnormal value on the oral GTT

Goals are to:

- Contribute to fetal well-being
- Prevent ketosis
- Provide adequate weight gain
- Achieve normoglycemia

Caloric Requirements Needed Based on Ideal Body Weight

The suggested caloric intake is approximately:

- 30 kcal per kg current weight per day in pregnant women (BMI 22 to 27)
- 24 kcal per kg current weight per day in overweight pregnant women (BMI 27 to 29)
- 12 to 15 kcal per kg current weight per day for morbidly obese pregnant women (BMI >30)
- 40 kcal per kg current weight per day in pregnant women with a BMI less than 22

1. Carbohydrates
   - Approximately 35 to 40 percent of calories

2. Protein
   - Approximately 20 percent of calories

3. Fat
   - Approximately 40 percent of calories

According to Jovonovic (2006), 75 to 80 percent of women with GDM will achieve normoglycemia with the above suggested caloric distribution. Postprandial blood glucose concentrations are directly dependent upon the carbohydrate content of a meal. The postprandial glucose rise, therefore, can be blunted if the diet is carbohydrate restricted. Complex carbohydrates, such as those in starches and vegetables, are more nutrient dense and raise postprandial blood glucose concentrations less than simple sugars.
Caloric Distribution

*Breakfast*
- Approximately 10% of total calories
- Carbohydrate limited, due to time of greatest insulin resistance

*Lunch*
- 30% of total calories

*Supper*
- 30% of total calories

*Snacks*
- Approximately 30% of calories are distributed as needed
- Leftover calories

II. Monitoring

Glucose Monitoring Guidelines
- Daily monitoring documented on a log:
  - Upon awakening
  - 1-hour post meals
  - The difference between measuring 1-hour versus 2-hours postprandially has not been established
- Postprandial glucose control leads to improve outcomes (decreases incidence of large-for-gestational age, decreases risk for cesarean delivery)

Degree of fasting does not predict the need for insulin therapy (Jovonovic, 2006)

III. A1c Measurements
- Utilized as feedback, evaluate merit of glucose monitoring
- A1c is lower in pregnancy (average, 20% lower)
- Rise in red cell mass in 1st trimester and decrease in red blood cell life span

IV. Exercise
- ADA approves moderate exercise in individuals without medical or obstetrical contradictions to exercise

V. Medication Regimen

Insulin Therapy is the only recommended medical therapy approved in the United States.
Oral anti-hyperglycemic agents are not endorsed by the ADA or ACOG and have not been approved by the United States Food and Drug Administration.

A. Initiating Insulin Therapy

Start insulin therapy when glucose concentrations reach the values below in order to prevent macrosomia, shoulder dystocia, and/or birth trauma, despite MNT:

<table>
<thead>
<tr>
<th>JOVONOVIC, 2006</th>
<th>ACOG</th>
<th>ADA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting blood glucose concentration ≥ 90 (5 mmol/L)</td>
<td>Fasting glucose concentration ≥ 95 (5.3 mmol/L) or</td>
<td>Fasting plasma glucose concentration &gt; 105 (5.8 mmol/L) or</td>
</tr>
<tr>
<td>One-hour postprandial blood glucose concentration ≥ 120 (6.7 mmol/L)</td>
<td>One-hour postprandial glucose &gt;130 to 140 (7.2 to 7.8 mmol/L) or</td>
<td>One-hour postprandial plasma glucose &gt; 155 (8.6 mmol/L) or</td>
</tr>
<tr>
<td>The Texas Diabetes Council suggests following Jovonovic’s guidelines; Fasting hyperglycemia higher threshold (&gt;105 [&gt;5.8 mmol/L] versus ≥ 90-95 [≥ 5-5.3 mmol/L]) is associated with increased risk of macrosomia, and an increased risk of fetal death in the last trimester at times</td>
<td>Two-hour postprandial blood concentration ≥ 120 (6.7 mmol/L)</td>
<td>Two-hour postprandial plasma glucose &gt; 130 (7.2 mmol/L)</td>
</tr>
</tbody>
</table>

According to Jovonovic (2006), dosing varies according to degree of obesity, ethnic characteristics, and other demographic criteria. Specific guidelines are as follows:

- 50 to 90 units are typically utilized to achieve glucose control (type of insulin used is calculated based upon blood glucose values)
- If fasting glucose is high, it is recommended to add an intermediate-acting insulin, with an initial dose of 0.2 U/kg body weight (such as NPH insulin) before bedtime
- If postprandial blood glucose concentrations are high, regular insulin or insulin lispro before meals at a dose calculated to be 1.5 U per 10 grams carbohydrate in the breakfast meal and 1 U per 10 grams carbohydrate in the lunch and dinner meals is recommended
- If both preprandial and postprandial blood glucose concentrations are high or postprandial glucose levels can only be blunted if starvation ketosis occurs, then
  - Initiate a four injection per day regimen:
    - Consider administering a total dose of 0.7 U/kg up to week 18
    - 0.8 U/kg for weeks 18 to 26
    - 0.9 U/kg for weeks 26 to 36
    - 1.0 U/kg for weeks 36 to term
In a morbidly obese woman, the initial doses of insulin may need to be increased to 1.5 to 2.0 units/kg to overcome the combined insulin resistance of pregnancy and obesity.

Insulin is typically divided into the following schedule:

- 45 percent as NPH insulin (30 percent before breakfast and 15 percent before bedtime) and
- 55 percent as preprandial regular insulin
  - 22 percent before breakfast
  - 16.5 percent before lunch
  - 16.5 percent before dinner

Four-times daily regimen improves glycemic control and perinatal outcome better than a twice-daily regimen.

Dosing is based on frequent self monitoring.

Four or more glucose measurements each day are recommended.

Twin gestations have an approximate doubling of the insulin requirements.

**Insulin Types**

- Human insulin should be prescribed since it is the least immunogenic of the commercially available insulin preparations.
- Insulin analogs like Lispro, Aspart, Glulysine are comparable in immunogenicity to human Regular insulin.
- Only Lispro and Aspart have been investigated in pregnancy; studies denote acceptable safety profiles, lower risk for postprandial hypoglycemia, minimal transfer across the placenta, no evidence of teratogenesis.
- Long-acting insulin analogs (Glargine, Detemir) have not been studied extensively in pregnancy; therefore, the use of human NPH insulin as part of a multiple injection regimen in pregnant women is recommended.
- Lente insulins have too much variability in effect and therefore are not recommended (Jovonovic, 2006).

**B. Treating Hypoglycemia** (Jovonovic, 2006)

Remote from meal or snack time Hypoglycemia should be treated by:

- Administering 10 to 20 g of carbohydrate immediately.
- Consider use of correction factor of one unit of rapid-acting insulin lowers blood glucose by 25 mg/dL.
JOVONOVIC’S GUIDELINES

<table>
<thead>
<tr>
<th>Glucose Range</th>
<th>Insulin Adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>If glucose &lt;50 mg/dL</td>
<td>Subtract 2 units of regular insulin from the dose of insulin given before the meal</td>
</tr>
<tr>
<td>For glucose 50 to 75 mg/dL</td>
<td>Subtract one unit from the dose of insulin given before the meal</td>
</tr>
<tr>
<td>For glucose 75 to 100 mg/dL</td>
<td>It is not recommended to change insulin dose</td>
</tr>
<tr>
<td>For glucose 100 to 125 mg/dL</td>
<td>Add one unit regular insulin to the dose of insulin given before the meal</td>
</tr>
<tr>
<td>For glucose 100 to 150 mg/dL</td>
<td>Add two units regular insulin to the dose of insulin given before the meal.</td>
</tr>
</tbody>
</table>

Jovonovic (2006) does not recommend the use of insulin pumps (expensive and do not clearly provide a benefit in the setting of GDM).

C. Oral Anti-Hyperglycemic Agents

- The ADA and ACOG do not endorse the use of oral anti-hyperglycemic agents during pregnancy
- Oral anti-hyperglycemic agents have not approved by the Unites States Food and Drug Administration (ACOG, 2001, ADA, Suppl, 2004)
- Tolbutamide and chlorpropamide are not to be used for pregnancy; the agents are known to cross the placenta and can cause fetal hyperinsulinemia, which often leads to other complications such as neonatal hypoglycemia and macrosomia (Garcia-Bournissen, et al., 2003; Zucker & Simon, 1968)
- Glyburide has minimal transplacental passage; some neonatal hypoglycemia (Elliot, Langer, et al., 1991); the Fifth ACOG International Workshop cautioned its use until there is more research
- Metformin should not be used in GDM; currently, there are no randomized trials evaluating its use in GDM; a trial in Australia may be completed in 2007 and may elucidate the safety and efficacy of Metformin in GDM; its use in GDM is not recommended
- Acarbose is not recommended for use at this time; some of the drug may be absorbed systemically
- Thiazolidinediones, glinides, GLP-1 not recommended during pregnancy; they are considered experimental

VI. Management During the Peripartum Period

- Hold insulin during labor and delivery
- Normal saline often achieves normoglycemia
Avoid hyperglycemia during labor in order to prevent fetal hyperinsulinemia, neonatal hypoglycemia, hyperbilirubinemia, hypocalcemia, erythremia

Keep maternal blood glucose concentration between 70 and 90 mg/dL

VII. Measures After Delivery

- Blood glucose should be measured on the day after delivery to assess for hyperglycemia; use criteria for diabetes diagnosis for nonpregnant individuals
- A regular diet can be considered for the GDM woman postpartum
- Patient should assess blood glucose at home for a few weeks post discharge (especially those that were diagnosed early in their gestation or who necessitated insulin therapy); remind patient to report any high values

VIII. Risk of Diabetes Postpartum

One third to two-thirds of women with GDM will have GDM in a subsequent pregnancy (Philipson & Super, 1989; Moses, 1996; Catalano, et al., 1991). They tend to be older, more parous, and have a greater increase in weight between their pregnancies than women without a recurrence. Higher infant birth weight in the index pregnancy and higher maternal prepregnancy weight have also been associated with recurrent GDM.

- Parity, habitus, large birth weight, and diabetes in a first-degree relative are less correlated with later diabetes.
- GDM is also a risk factor for the development of type 1 diabetes. Specific HLA alleles (DR3 or DR4) may predispose to the development of type 1 diabetes postpartum, as does the presence of islet-cell autoantibodies (Ferber, et al., 1999).
- Progestin-only (but not combined estrogen-progestin) oral contraceptives (OCs) have been associated with an increased risk of developing type 2 diabetes in women with recent GDM. In a study of Hispanic women with recent GDM who were breast feeding, the use of progestin-only OCs was associated with an increased risk of type 2 diabetes (Kjos, et al, 1998). Generalizability to other women is not yet clear.

XI. GDM Follow-Up

All women with known diagnosis of GDM should undergo

- An oral glucose tolerance test using a two-hour 75 gram oral glucose tolerance test
  - 6-12 weeks after delivery or after cessation of breast feeding.
  - Women who have an abnormal oral glucose tolerance test are therefore noted as having impaired glucose tolerance or a diagnosis of diabetes mellitus, based on ADA diagnostic criteria.
  - Those with impaired glucose tolerance should be counseled about their subsequent risk for developing overt diabetes. (See algorithm for Prevention and Delay of Type 2 Diabetes in Children and Adults with Impaired Fasting Glucose (IFG) and/or Impaired Glucose Tolerance.)
Diabetes Education should be ordered to include meal planning to achieve ideal body weight along with other appropriate therapies as indicated on TDC algorithms for diabetes management.

- Education should include advice regarding contraception and future pregnancy plans.
- Education should include the risk towards the development of GDM in subsequent pregnancies as well as their risk for the development of type 2 diabetes in the future.
- Blood glucose measurement should be done at least at three year intervals; with hyperglycemia, more frequent testing is warranted.
REFERENCES


**Pregestational Diabetes Guidelines**

Pregestational diabetes encompasses a diagnosis of type 1 or type 2 diabetes prior to gestation. It should be noted that undiagnosed pregestational diabetes is suspected in the presence of maternal hyperglycemia and fetal anomalies. The risk of fetal anomalies is therefore increased when fasting hyperglycemia is found at GDM diagnosis (Jovonovic, 2006; Sheffield, et al., 2002).

Suspect type 1 diabetes with the presence of the following (Jovonovic, 2006):

- Serum anti-insulin antibodies and anti-islet cell antibodies may be helpful for identifying type 1 diabetes in pregnant women
- GDM in lean women
- Diabetic ketoacidosis during pregnancy
- Severe hyperglycemia during pregnancy requiring large doses of insulin
- Postpartum hyperglycemia
- Type 2 diabetes and monogenic diabetes (e.g., maturity onset diabetes of the young and permanent neonatal diabetes) is difficult to distinguish from GDM
- These pregnant women tend to be lean (while obesity is a risk factor for type 2 diabetes)
- Should be followed for glucose status to evaluate for other disorders

Women should be directed to (Jovonovic, 2006):

- Continue self blood glucose monitoring postpartum to document persistent hyperglycemia
- Consider fasting blood glucose testing every 6 to 12 months for the next 5 to 10 years if their blood glucose is normal during this period

<table>
<thead>
<tr>
<th>Pregestational Diabetes General Guidelines</th>
<th>Based on American College of Obstetricians &amp; Gynecologists, 2006</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendations Based on Limited or Inconsistent Scientific Evidence</td>
<td>Level B</td>
</tr>
<tr>
<td>Patient Visits</td>
<td>Q 1-2 weeks during 1st two trimesters; weekly after 28-30 weeks of gestation</td>
</tr>
<tr>
<td>Caloric Requirements</td>
<td>1. Nutrition consult warranted</td>
</tr>
<tr>
<td>----------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td></td>
<td>2. 300 kcal higher than basal in patients with singleton fetus</td>
</tr>
<tr>
<td></td>
<td>Normal Weight</td>
</tr>
<tr>
<td></td>
<td>&lt; 90% desirable body weight</td>
</tr>
<tr>
<td></td>
<td>&gt; 120% of desirable body weight</td>
</tr>
<tr>
<td>Caloric Composition</td>
<td>Complex, high-fiber carbohydrates</td>
</tr>
<tr>
<td></td>
<td>Protein</td>
</tr>
<tr>
<td></td>
<td>Unsaturated fats</td>
</tr>
<tr>
<td>Caloric Distribution</td>
<td>1. 10-20% – Breakfast</td>
</tr>
<tr>
<td></td>
<td>2. 20-30% – Lunch</td>
</tr>
<tr>
<td></td>
<td>3. 30-40% – Supper</td>
</tr>
<tr>
<td></td>
<td>4. 30% – Snacks, prevent nocturnal hypoglycemia</td>
</tr>
<tr>
<td>Insulin Therapy Needs</td>
<td>First trimester</td>
</tr>
<tr>
<td></td>
<td>Second trimester</td>
</tr>
<tr>
<td></td>
<td>Third trimester</td>
</tr>
<tr>
<td>Maintain Glucose at Near Normal Levels</td>
<td>1. Fasting &lt; 95 mg/dL or less</td>
</tr>
<tr>
<td></td>
<td>2. Premeal &lt; 100 mg/dL or less</td>
</tr>
<tr>
<td></td>
<td>3. 1-hour postprandial &lt; 140 or less</td>
</tr>
<tr>
<td></td>
<td>4. 2-hour postprandial &lt; 120 mg/dL or less</td>
</tr>
<tr>
<td></td>
<td>5. HS, not to decrease &lt; 60 mg/dL</td>
</tr>
<tr>
<td></td>
<td>6. Average maintained @ 100 mg/dL</td>
</tr>
<tr>
<td></td>
<td>7. A1c no higher than 6%</td>
</tr>
<tr>
<td>Induction of Labor</td>
<td>Note recommended for suspected fetal macrosomia</td>
</tr>
<tr>
<td>Monitoring</td>
<td>Antepartum fetal monitoring, nonstress test, biophysical profile, contraction stress test, fetal movement counting</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Maintain Glucose Control Near Physiologic Levels Before, During Pregnancy</td>
<td>Decreases spontaneous abortion, fetal malformation, fetal macrosomia, intrauterine fetal death, neonatal morbidity</td>
</tr>
<tr>
<td>Counseling</td>
<td>Teach hypoglycemia &amp; preconceptional counseling to patient and families</td>
</tr>
<tr>
<td>Cesarean Delivery</td>
<td>For estimated fetal weight &gt; 4500 g</td>
</tr>
<tr>
<td>Insulin Therapy During Labor &amp; Delivery</td>
<td>Prior to active labor</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>With active labor or blood glucose &lt; 70 mg/dl</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>DKA during Pregnancy</td>
<td>Laboratory assessment</td>
</tr>
<tr>
<td></td>
<td>Document acidosis</td>
</tr>
<tr>
<td></td>
<td>Insulin therapy</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>Fluid therapy</td>
<td>1. NS, 1 L in 1st hr</td>
</tr>
<tr>
<td></td>
<td>3. 250 ml/h until 80% replaced</td>
</tr>
<tr>
<td>Glucose</td>
<td>Start D5% NS when glucose reaches 250 mg/dL</td>
</tr>
<tr>
<td>Potassium</td>
<td>If normal or reduced, start infusion @ 15-20meq/h; If elevated, wait until normal levels, then add in IV in concentration of 20-30 meq/l</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>44 mEq (one ampule) to L of .45NS if pH &lt; 7.1</td>
</tr>
</tbody>
</table>
Self Monitoring Blood Glucose (SMBG)

Since diabetes is primarily a disease controlled by the patient, it is extremely important for the patient to monitor their diabetes on a day-to-day basis. The frequency of self monitoring blood glucose (SMBG) depends on the type of diabetes and the level of blood glucose control desired. One of the main purposes of blood glucose measurements is to assist in making adjustments in treatment, through either dietary intake, medications, activity levels or a combination of all 3 factors.

**FREQUENCY OF TESTING**

**Type 1**
- Ideally, test before and after meals and at bedtime.
- For those patients on bedtime insulin, checking a 3:00 a.m. blood glucose is necessary at least 1x/week. If the patient is awakened during the night with signs and symptoms of hypoglycemia, if the fasting glucose continues to rise with increasing bedtime insulin or if the patient complains of restless sleep, a glucose check at 3:00 a.m. is required to better determine correct insulin dosage.
- Once stable, patients should alternate times to SMBG throughout the day.
- Test before, during, and after vigorous activity to avoid hypoglycemia.
- Increased testing is indicated if the patient has hypoglycemic or hyperglycemic symptoms and during periods of illness, injury, or stress.

**Type 2**
Recommended for those on insulin or oral medications and during periods of stress, such as infection or trauma.
- Depending on degree of control desired, test glucose before breakfast and before supper.
- Some patients may require testing before each meal and at bedtime.
- For those patients on bedtime insulin, checking blood sugar at 3:00 a.m. is necessary at least 1x/week. If the patient is awaken during the night with signs and symptoms of hypoglycemia, if the fasting glucose continues to rise with increasing bedtime insulin, or if the patient complains of restless sleep or awakening with a headache, a glucose check at 3:00 a.m. is required to better determine the correct insulin dosage.
- More frequent blood glucose measurements are indicated when changes are made in medication or insulin.
- If blood glucose levels are stable, test before breakfast and before supper, 2-3x/week.
Use of SMBG for those who are being treated only with a healthy eating plan is controversial. Many patients may benefit by measuring their responses to different foods and activities. The immediate feedback of SMBG can assist patients with making appropriate dietary modifications to improve future glucose results. They will want to SMBG more frequently during periods of stress or illness.

**Glycemic Control Goals (nonpregnant adults)**

<table>
<thead>
<tr>
<th>TIME OF DAY</th>
<th>NORMAL VALUES NON-DIABETIC</th>
<th>ADA* GOALS</th>
<th>AACE** GOALS</th>
<th>ACTION SUGGESTED IF:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting</td>
<td>&lt; 100 mg/dL</td>
<td>90 – 130 mg/dL</td>
<td>&lt; 110 mg/dL</td>
<td>&lt; 80 or &gt; 140 mg/dL</td>
</tr>
<tr>
<td>Preprandial (Before meals and snacks)</td>
<td>&lt; 110 mg/dL</td>
<td>70 – 130 mg/dL</td>
<td>&lt; 110 mg/dL</td>
<td>&lt; 80 or &gt; 140 mg/dL</td>
</tr>
<tr>
<td>After meals</td>
<td>70-140 mg/dL</td>
<td>&lt; 180 mg/dL (peak)*</td>
<td>&lt; 140 mg/dL (2 hrs. after meal)</td>
<td>Determined by clinician</td>
</tr>
<tr>
<td>Bedtime</td>
<td>&lt; 110 mg/dL</td>
<td>110-150 mg/dL</td>
<td>unavailable</td>
<td>&lt; 110 or &gt; 160 mg/dL</td>
</tr>
</tbody>
</table>

A1c (also called glycosylated hemoglobin A1c, HbA1c or glycohemoglobin A1c) | < 6% | < 7% (a) or as close to normal (<6%) without significant hypoglycemia (b) | ≤ 6.5%*** | > 7%

*** AACE (2002) and the Texas Diabetes Council (2007).

- a. For patients in general with diabetes
- b. For the individual with diabetes

---

**See Glycemic Control Algorithm:**

**Glycemic Control for Type 2 Diabetes in Children and Adults**

A ten-year study showed that patients with type 1 who kept their blood glucose near these levels developed significantly fewer diabetes-related complications. Even if blood glucose levels were not in the desirable range, any lowering of blood glucose reduced the chances of developing complications.

In the following groups of people, glycemic control goals may be more relaxed

- In the elderly, infants and toddlers;
- In patients with hypoglycemic unawareness;
• In patients with advanced renal or cardiac disease;
• In patients experiencing difficulties with following their treatment plan.

To avoid symptoms of hyperglycemia in these groups, keeping blood glucose under 150 mg/dL is recommended.

Special considerations in SMBG

1. It is often helpful for patients to document their glucose results in a written log. This activity can assist patients in seeing glucose patterns during certain times of the day. It can also be helpful in making correlations between medications, dietary intake, activity and resulting glucose levels.

2. If available, patients can benefit from utilizing computer-downloading features of the meters. The glucose data can be grouped based on time of day, day of the week, weekends vs. weekdays, as well as providing markers of meals, activity and medication times. These computer programs are available for health care professionals’ use in the office as well as being available to the patients to use at home.

3. Assess your patient’s level of competence and select a glucose meter that best meets their needs. Not all patients will benefit from added features and the “extras” may just confuse the patient more.

4. Instruct the patient on the proper use of their particular glucose meter. Encourage the patient to read the instruction manual and know how to set the correct date and time, how to recall data, how to change the battery and how to trouble-shoot the meter for problems. Be sure the patient is aware that some meters may read the glucose results in mmol rather than mg/dL.

5. Instruct patients to check the expiration date and the proper means of storage and handling for their glucose monitoring strips.

6. Instruct patients on interpreting the glucose results. It is not enough to just monitor the glucose. The patient needs to understand the correlation between the food they eat, the medications they take, their activity level and the resulting glucose level. The patient must be provided with guidelines on adjusting their insulin dosages for optimal glucose control.

Pregnancy in Preexisting Diabetes — Type 1 and Type 2

• Tight blood glucose control before conception and throughout pregnancy is critical for optimal outcomes.
• Testing before each meal, 1-2 hours after meals and at bedtime every day and 1-2x/week at 3:00 a.m. are optimal.
• Insulin treatment is recommended if the fasting glucose >105 mg/dL and/or 2 hour postprandial levels are >120 mg/dL.
Gestational Diabetes

- A controversy exists regarding the best times to monitor. Fasting and 2-hour post-meal blood glucose testing are most commonly used. Studies have shown that fasting and 1 hour after meal testing resulted in improved glycemic control.
- Insulin treatment is recommended if fasting glucose >105 mg/dL and/or 2-hour postprandial levels are >120 mg/dL.

Monitoring in the hospital setting

Managing hospitalized patients with diabetes should include capillary blood glucose measurements at the bedside. This should be part of the patients’ “vital signs.” Results can be obtained rapidly, and therapeutic decisions can be made that result in improved management and shortened hospital stays. Using capillary blood glucose tests instead of venipunctures enhances the patients’ comfort and provides an opportunity for the patient to learn SMBG. Adequately trained personnel must perform bedside glucose tests. According to the American Diabetes Association in 2003, the “use of bedside blood glucose monitoring requires 1) clear administrative responsibility for the procedure, 2) a well-defined policy/procedure manual, 3) a training program for those personnel doing the testing, 4) quality control procedures, and 5) regularly scheduled equipment maintenance.” Frequency of measurement should be individualized based on each patient’s condition and health care provider recommendation.

Glucose monitoring systems cannot and should not replace laboratory glucose determinations, but they can greatly reduce their frequency and supplement expensive laboratory data.

A1c and self-monitoring of blood glucose (SMBG)

Another means of managing diabetes is with a hemoglobin A1c test, or often simply called an A1c. This test reflects the glucose (or blood sugar) control over the past 3 months. Testing the A1c level every 3 months is a good way to understand how well glucose levels are controlled over a long period and can help understand how SMBG frequency, timing, meal plans, and medications may need to be changed or adjusted.

Reasons to check blood glucose more frequently

- When diabetes medicine changes
- When initiating other kinds of medicines
- When making dietary changes
- When exercise routine or activity level changes
- When level of stress increases
- When the patient is sick. When ill, even without eating, glucose levels may run high, so testing is important!
Other reasons to check blood glucose

- When symptoms of hypoglycemia occur, which include dizziness, shaking, sweating, chills, and confusion
- When symptoms of hyperglycemia occur, which include sleepiness, blurred vision, frequent urination, and excessive thirst
- To learn how meals, physical activity, and medicine affect blood glucose levels
- To document how well blood glucose is controlled
- When patients have a job in which poor control could cause safety problems
- To help a patient decide if it is safe to drive or perform other tasks that require concentration if taking insulin or have had hypoglycemia in the past


The National Committee for Clinical Laboratory Standards: Ancillary (Bedside) Blood Glucose Testing in Acute and Chronic Care Facilities: Approved Guideline. Villanova, PA, National Committee for Clinical Laboratory Standards, 1994
Hypoglycemia

**BLOOD GLUCOSE LESS THAN 70 MG/DL**

<table>
<thead>
<tr>
<th>Onset:</th>
<th>Sudden</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symptoms:</strong></td>
<td><strong>Causes:</strong></td>
</tr>
<tr>
<td>Shaky</td>
<td>Delayed or missed meal</td>
</tr>
<tr>
<td>Tired/sleepy</td>
<td>Too much exercise</td>
</tr>
<tr>
<td>Grouchy/irritable</td>
<td>Too much insulin/diabetes pill</td>
</tr>
<tr>
<td>Rapid heart beat</td>
<td></td>
</tr>
<tr>
<td>Sweaty</td>
<td></td>
</tr>
<tr>
<td>Hungry</td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td></td>
</tr>
<tr>
<td>Poor concentration</td>
<td></td>
</tr>
<tr>
<td>Numbness or tingling around mouth or tongue</td>
<td></td>
</tr>
</tbody>
</table>

**Treatment:**

- Eat a food containing 15 gm fast-acting carbohydrate (sugar) —
  - 1/2 c. juice or regular soda
  - 6-7 hard candies (not sugar free)
  - 5 sugar cubes
  - 3 glucose tablets (5 grams glucose each)
  - 1 small box of raisins
  - 8 oz. skim milk

Patients should always carry quick-acting carbohydrate (sugar). If they get symptoms, they should eat one of the foods listed above. They should feel better in 15 minutes. Recheck blood sugar. May repeat if needed. If the next meal is more than one hour away, most can eat one of the following: 1 peanut butter sandwich, cheese and crackers, or drink 1 cup skim milk.

If patient is unable to eat/drink but still conscious, a helper can quickly apply glucose gel or cake frosting to the gums and massage.

**DO NOT GIVE FLUIDS IF UNCONSCIOUS/UNABLE TO SWALLOW.** If unable to swallow, a family member/friend must inject 1 vial of glucagon subcutaneously. Instruct patient to notify their health care provider if they have three episodes of hypoglycemia within a one-week period or if one episode results in loss of consciousness.

**PREVENTION:**

- Follow meal plan, don’t skip
- Take medication as prescribed
- Monitor blood sugar regularly
# Hyperglycemia

## Blood Glucose More Than 240 mg/dl

<table>
<thead>
<tr>
<th>Onset:</th>
<th>Can develop slowly, getting a little higher each day. Can develop quickly after a big meal or illness.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms:</td>
<td>Thirstier than usual</td>
</tr>
<tr>
<td></td>
<td>Urinary frequency</td>
</tr>
<tr>
<td></td>
<td>Hungrier than usual</td>
</tr>
<tr>
<td></td>
<td>More tired/sleepier than usual</td>
</tr>
<tr>
<td></td>
<td>Blurred vision</td>
</tr>
<tr>
<td></td>
<td>Dry, itchy skin</td>
</tr>
<tr>
<td></td>
<td>Cuts/sores that heal slowly</td>
</tr>
<tr>
<td>Causes:</td>
<td>Too much food</td>
</tr>
<tr>
<td></td>
<td>Not enough insulin/diabetes pill</td>
</tr>
<tr>
<td></td>
<td>Too little/no exercise</td>
</tr>
<tr>
<td></td>
<td>Infection/stress/illness</td>
</tr>
<tr>
<td>Treatment:</td>
<td>Take diabetes medication</td>
</tr>
<tr>
<td></td>
<td>Drink more water</td>
</tr>
<tr>
<td></td>
<td>Identify possible causes</td>
</tr>
<tr>
<td></td>
<td>Walk or mild physical activity unless glucose &gt; 300 mg/dL or as health care provider advised</td>
</tr>
</tbody>
</table>

If blood sugar suddenly goes over 200 mg/dL, continue with treatment plan. Check sugars frequently to assure they are returning to normal level. Encourage more sugar-free fluids; for example, 8 oz. of water per hour. Notify health care provider if blood sugars are averaging over 200 mg/dL for a week or more.

**Prevention:**
- Follow meal plan
- Monitor blood sugar regularly
- Regular exercise as advised by health care provider
- Take medications as prescribed.
**Vibrio vulnificus**

**What is *Vibrio vulnificus***?

*Vibrio vulnificus* is a bacterium in the same family as those that cause cholera. It normally lives in warm seawater and is part of a group of vibrios that are called “halophilic” because they require salt.

**What type of illness does *V. vulnificus* cause?**

*V. vulnificus* can cause disease in those who eat contaminated seafood or have an open wound that is exposed to seawater. Among healthy people, ingestion of *V. vulnificus* can cause vomiting, diarrhea, and abdominal pain. In immunocompromised persons, particularly those with chronic liver disease, *V. vulnificus* can infect the bloodstream, causing a severe and life-threatening illness characterized by fever and chills, decreased blood pressure (septic shock), and blistering skin lesions. *V. vulnificus* bloodstream infections are fatal about 50% of the time.

*V. vulnificus* can also cause an infection of the skin when open wounds are exposed to warm seawater; these infections may lead to skin breakdown and ulceration. Persons who are immunocompromised are at higher risk for invasion of the organism into the bloodstream and potentially fatal complications.

**How common is *V. vulnificus* infection?**

*V. vulnificus* is a rare cause of disease, but it is also underreported. Between 1988 and 1995, CDC received reports of over 300 *V. vulnificus* infections from the Gulf Coast states, where the majority of cases occur. There is no national surveillance system for *V. vulnificus*, but CDC collaborates with the states of Alabama, Florida, Louisiana, Texas, and Mississippi to monitor the number of cases of *V. vulnificus* infection in the Gulf Coast region.

**How do persons get infected with *V. vulnificus***?

Persons who are immunocompromised, especially those with chronic liver disease, are at risk for *V. vulnificus* when they eat raw seafood, particularly oysters. A recent study showed that people with these pre-existing medical conditions were 80 times more likely to develop *V. vulnificus* bloodstream infections than were healthy people. The bacterium is frequently isolated from oysters and other shellfish in warm coastal waters during the summer months. Since it is naturally found in warm marine waters, people with open wounds can be exposed to *V. vulnificus* through direct contact with seawater. There is no evidence for person-to-person transmission of *V. vulnificus*.

**How can *V. vulnificus* infection be diagnosed?**

*V. vulnificus* infection is diagnosed by routine stool, wound, or blood cultures; the laboratory should be notified when this infection is suspected by the physician, since a special growth medium can be used to increase the diagnostic yield. Doctors should have a high suspicion for this organism when patients present with gastrointestinal illness, fever, or shock following the ingestion of raw seafood,
especially oysters, or with a wound infection after exposure to seawater.

**How is *V. vulnificus* infection treated?**

If *V. vulnificus* is suspected, treatment should be initiated immediately because antibiotics improve survival. Aggressive attention should be given to the wound site; amputation of the infected limb is sometimes necessary. Clinical trials for the management of *V. vulnificus* infection have not been conducted. The antibiotic recommendations below come from documents published by infectious disease experts; they are based on case reports and animal models.

- Culture of wound or hemorrhagic bullae is recommended, and all *V. vulnificus* isolates should be forwarded to a public health laboratory
- Blood cultures are recommended if the patient is febrile, has hemorrhagic bullae, or has any signs of sepsis

**Antibiotic therapy:**

- Doxycycline (100 mg p.o./IV twice a day for 7-14 days) and a third-generation cephalosporin (e.g., ceftazidime 1-2 g IV/IM every eight hours) is generally recommended
- A single agent regimen with a fluoroquinolone such as levofloxacin, ciprofloxacin or gatifloxacin, has been reported to be at least as effective in an animal model as combination drug regimens with doxycycline and a cephalosporin
- Children, in whom doxycycline and fluoroquinolones are contraindicated, can be treated with trimethoprim-sulfamethoxazole plus an aminoglycoside
- Necrotic tissue should be debrided; severe cases may require fasciotomy or limb amputation

**Are there long-term consequences of *V. vulnificus* infection?**

*V. vulnificus* infection is an acute illness, and those who recover should not expect any long-term consequences.

**What can be done to improve the safety of oysters?**

Although oysters can be harvested legally only from waters free from fecal contamination, even legally harvested oysters can be contaminated with *V. vulnificus* because the bacterium is naturally present in marine environments. *V. vulnificus* does not alter the appearance, taste, or odor of oysters. Timely, voluntary reporting of *V. vulnificus* infections to CDC and to regional offices of the Food and Drug Administration (FDA) will help collaborative efforts to improve investigation of these infections. Regional FDA specialists with expert knowledge about shellfish assist state officials with tracebacks of shellfish and, when notified rapidly about cases, are able to sample harvest waters to discover possible sources of infection and to close oyster beds when problems are identified. Ongoing research may help us to predict environmental or other factors that increase the chance that oysters carry pathogens.
How can I learn more about *V. vulnificus*?

You can discuss your medical concerns with your doctor or other health care provider. Your local city or county health department can provide information about this and other public health problems that are occurring in your area. Information about the potential dangers of raw oyster consumption is available 24 hours a day from the FDA's Seafood Hotline (telephone 1-800-332-4010); FDA public affairs specialists are available at this number between 12 and 4 p.m. Monday through Friday. Information is also available on the internet at: [http://vm.cfsan.fda.gov](http://vm.cfsan.fda.gov).

Some tips for preventing *V. vulnificus* infections, particularly among immunocompromised patients, including those with underlying liver disease:

- Do not eat raw oysters or other raw shellfish.
- Cook shellfish (oysters, clams, mussels) thoroughly:
  - For shellfish in the shell, either a) boil until the shells open and continue boiling for 5 more minutes, or b) steam until the shells open and then continue cooking for 9 more minutes. Do not eat those shellfish that do not open during cooking. Boil shucked oysters at least 3 minutes, or fry them in oil at least 10 minutes at 375°F.
- Avoid cross-contamination of cooked seafood and other foods with raw seafood and juices from raw seafood.
- Eat shellfish promptly after cooking and refrigerate leftovers.
- Avoid exposure of open wounds or broken skin to warm salt or brackish water, or to raw shellfish harvested from such waters.
- Wear protective clothing (e.g., gloves) when handling raw shellfish.

Date: October 25, 2005

*Content source:* National Center for Infectious Diseases/Division of Bacterial and Mycotic Diseases
Chronic Complications of Diabetes

High levels of sugar (glucose) in the blood vessels over time lead to a variety of medical problems because too much sugar damages the lining of large and tiny blood vessels and other body tissues. Fortunately, early diagnosis and daily blood sugar control are possible with good nutrition, daily physical activity, weight control, taking prescribed medication and self-testing of blood sugar. Daily diabetes care means living a healthy lifestyle, often one that benefits the whole family.

Heart disease

- Heart disease is the most common reason that adults with diabetes die at an earlier age. Adults with diabetes are two to four times more likely to die from heart disease than people without diabetes.

Stroke

- The risk for stroke is also 2 to 4 times higher among people with diabetes. Having high blood pressure — higher than 130/80 mm Hg — or high blood fats (lipids) further increases the chances for persons with diabetes to have heart disease and/or stroke.

Blindness

- Diabetes is the leading cause of blindness among adults because high sugar levels damage tiny blood vessels in the retina at the back of the eye.

Kidney disease

- Diabetes is the leading cause of end stage renal disease (ESRD) in the United States also because high sugar levels damage tiny blood vessels in the kidneys. Many people then require dialysis or kidney transplantation.

Neuropathy

- About 60% to 70% of people with diabetes have mild to severe forms of nervous system damage. The results of such damage include loss of usual sensation or feeling pain in the feet.
or hands, slowed digestion of food in the stomach, carpal tunnel syndrome, sexual impotence, and other nerve problems.

- Severe forms of diabetic nerve disease increase the risk of lower-limb (toe, foot, or leg) amputations.

Amputations

- More than half of nontraumatic lower-limb amputations in the United States occur among people with diabetes.
- Preventing amputations takes good blood sugar control, protective footwear (not walking around barefoot), daily inspections at home for cuts that a person might not feel, proper nail trimming, foot checks at every doctor visit, and a foot exam for sensation at least yearly.

**Dental disease**

- Periodontal or gum diseases are more common among people with diabetes than among people without diabetes.
- Almost one third of people with diabetes have severe gum diseases in which the teeth get too loose.

**Complications of pregnancy**

- Poorly controlled diabetes before and during the first trimester of pregnancy can cause major birth defects in 5% to 10% of pregnancies and miscarriage in 15% to 20% of pregnancies.
- Poorly controlled diabetes during the second and third trimesters of pregnancy can result in excessively large babies, posing a risk to the mother and the child.

**Other complications**

- Uncontrolled diabetes often leads to imbalances that can threaten life, such as diabetic ketoacidosis and nonketotic coma.
People with diabetes are more susceptible to infectious illnesses and, if they have these illnesses, are more seriously ill or die than people without diabetes. For example, they are more likely to be seriously ill with pneumonia or influenza than people who do not have diabetes.

**Targets for Preventing Chronic Complications**

- Monitor blood glucose.
- Control blood sugar (glucose) to near normal levels: blood sugars usually range from 70 to 100/110 mg/dL.
- Fill prescriptions and take medicines as prescribed; patient should tell doctor, pharmacist, or nurse about any problems related to getting or taking all the medicines.
- Get to and stay at a good body weight for height and build; a health care provider can measure body mass index (BMI) and help set an appropriate goal.
- Control blood pressure: goal is ≤ 130/80 mmHg.
- Control blood fats (lipids/cholesterol and triglycerides).
- Daily physical activity: 30 minutes a day of moderate to vigorous activity.
- Daily balanced eating habits; limit high fat foods.
6.4 Chronic Complications of Diabetes
Educating the Person with Diabetes

**PRINCIPLES OF ADULT EDUCATION**

Adults:

1. Are motivated to learn when they identify a need to learn or when social or professional pressures require new learning.
2. Are more likely to learn when content is organized in attractive learning packages.
3. Are self-directed and like to determine their specific learning experiences.
4. Enjoy small group interactions.
5. Draw their knowledge from years of experience and do not change readily.
6. Learn from others’ experiences as well as from their own.
7. Want practical answers to current problems and enjoy problem solving.
8. Like physical comfort and a relaxing atmosphere.
9. Like tangible rewards.
10. Hate to have their time wasted.

**STEPS TO AID RECALL**

1. Present instructions in a clear, simple manner.
2. Make advice detailed and specific.
3. Repeat and stress areas of particular importance.
4. Break instructions down into categories.
5. Check for understanding by asking person to repeat instructions and/or return demonstrations.
6. Utilize a variety of teaching methods such as diagrams, models, videos, etc., to reinforce verbal instructions.
7. Positively reinforce accurate recall of information.

**STRATEGIES TO INCREASE ADHERENCE**

1. Involve person in establishing treatment goals.
2. Keep it simple.
3. Tailor treatment to fit the person’s lifestyle.
4. Utilize reminders.
5. Seek and encourage family support.
6. Inform individual of desirable and undesirable effects of medications or treatments; let them know what to expect.
7. Monitor adherence.
8. Give feedback.
THE THREE DOMAINS OF LEARNING

1. Cognitive — learning that requires thinking
2. Affective — learning that requires a change in beliefs
3. Psychomotor — learning of skills and performance

THE EDUCATIONAL PROCESS

I. Assess
   A. Prior education and health beliefs
   B. Current routine and skills
      1. Medication(s)
      2. Monitoring
      3. Meal plan
      4. Exercise/activity level
   C. Physical limitations
      1. Altered vision
      2. Hearing loss
      3. Arthritis/tremors
      4. Memory deficits
      5. Concurrent illnesses
   D. Literacy and cognitive ability
   E. Psychosocial
      1. Support system
      2. Financial and transportation limitations
      3. Emotional status

II. Develop plan
   A. Goals and objectives
   B. Topics and content
   C. Activities
   D. Documentation
   E. References

III. Implement plan
   A. Keep in mind strategies that facilitate learning

IV. Evaluate
   A. Continued follow-up
   B. Referral to other agencies or health care providers
Teaching Strategies for Diverse Populations

An individualized education plan should be designed for every patient. The education plan should include basic skills and daily self-management practices.

Basic skills include:
- Safe practices of medication administration
- Meal planning
- Hypoglycemia management
- Self-blood glucose monitoring

Daily self-management practices include:
- Prevention and management of complications

Diabetes education is critical for proper disease management, but barriers to care often pose major obstacles towards achieving the implementation phase of AADE’s Standards of Care. Communication barriers, financial/legal problems, and cultural barriers are known to hinder medical care.

Minimizing the language barrier would expedite the teaching-learning process. The following suggestions can be used by health care providers whose cultural background is different from the patient’s.

1. Learn a few words, sentences or phrases in your target group’s language to start a positive working relationship.
2. Use appropriate terms when addressing or referring to diverse groups (i.e., Hispanic/Latinos, Puerto Ricans, Mexicans, Cubans, instead of minorities).
3. Demonstrate respect, tolerance, and acceptance of different ideas.
4. Judge the merits of behavior rather than letting tone of voice, communication style or accent influence your behavior.
5. Ask questions. “If you don’t ask, you won’t know.”
6. Observe; be aware of body language.
7. Establish relationships with several cultural groups to facilitate better understanding of the groups’ values, beliefs, and communication style.
8. Be patient. Don’t give up easily.
9. Develop culturally appropriate educational activities.
10. Identify appropriate communication channels for each ethnic group, i.e., church leaders or family.
11. Translate educational material appropriate for the ethnic group or subgroup. Spanish material may not be appropriate for various Hispanic cultures.
12. Identify culturally appropriate communication themes. Identify an adult translator preferably of the same gender.
13. Pamphlets and brochures should be well illustrated, geared to the appropriate reading level and in the preferred language.
14. Visit the patient’s home.

15. Recommend US Dept. of Health and Human Services’ *Diccionario de la Diabetes*, which is at a lower reading level for explanation of terminology in conjunction with frequently used terms by specific ethnic groups.

16. Recommend patient have an active support person who has an interest in learning and assisting the patient in every aspect of diabetes self-management.
National Standards for Diabetes Self-Management Education

**STANDARDS AND REVIEW CRITERIA**

**MARK PETROW, PHD**
**JOHN D. PETTE, PHD**
**DIANE READER, RD, CDE**
**LINDA M. SIMINERO, PHD, RN, CDE**
**KATIE WEINGER, EDD, RN**
**MICHAEL A. WEISS, JD**

Diabetes self-management education (DSME) is a critical element of care for all people with diabetes and is necessary in order to improve patient outcomes. The National Standards for DSME are designed to define quality diabetes self-management education and to assist diabetes educators in a variety of settings to provide evidence-based education. Because of the dynamic nature of health care and diabetes-related research, these Standards are reviewed and revised approximately every 5 years by key organizations and federal agencies within the diabetes education community.

A Task Force was jointly convened by the American Association of Diabetes Educators and the American Diabetes Association in the summer of 2006. Additional organizations that were represented included the American Dietetic Association, the Veteran’s Health Administration, the Centers for Disease Control and Prevention, the Indian Health Service, and the American Pharmaceutical Association. Members of the Task Force included a person with diabetes; several health services researchers/behaviorists, registered nurses, and registered dietitians; and a pharmacist.

The Task Force was charged with reviewing the current DSME standards for their appropriateness, relevance, and scientific basis. The Standards were then reviewed and revised based on the available evidence and expert consensus. The committee convened on 31 March 2006 and 9 September 2006, and the Standards were approved 25 March 2007.

**DEFINITION AND GOALS** — Diabetes self-management education (DSME) is the ongoing process of facilitating the knowledge, skill, and ability necessary for diabetes self-care. This process incorporates the needs, goals, and life experiences of the person with diabetes and is guided by evidence-based standards. The overall objectives of DSME are to support informed decision-making, self-care behaviors, problem-solving, and active collaboration with the health care team to improve clinical outcomes, health status, and quality of life.

**GUIDING PRINCIPLES** — Before the review of the individual Standards, the Task Force identified overriding principles based on existing evidence that would be used to guide the review and revision of the DSME Standards. These are:

1. Diabetes education is effective for improving clinical outcomes and quality of life; at least in the short-term (1–7).
2. DSME has evolved from primarily didactic presentations to more theoretically based empowerment models (3,8).
3. There is no one “best” education program or approach; however, programs incorporating behavioral and psychosocial strategies demonstrate improved outcomes (9–11). Additional studies show that culturally and age-appropriate programs improve outcomes (12–16) and that group education is effective (4,6,7,17,18).
4. Ongoing support is critical to sustain progress made by participants during the DSME program (3,13,19,20).
5. Behavioral goal-setting is an effective strategy to support self-management behaviors (21).

**STANDARDS**

**Structure**

Standard 1. The DSME entity will have documentation of its organizational structure, mission statement, and goals and will recognize and support quality DSME as an integral component of diabetes care.

Documentation of the DSME organizational structure, mission statement, and goals can lead to efficient and effective provision of services. In the business literature, case studies and case report investigations on successful management strategies emphasize the importance of clear goals and objectives, defined relationships and roles, and managerial support (22–25). While this concept is relatively new in health care, business and health policy experts and organizations have begun to emphasize written commitments, policies, support, and the importance of outcome variables in quality improvement efforts (22,26–37). The continuous quality improvement literature also stresses the importance of developing policies, procedures, and guidelines (22,26).

Documentation of the organizational structure, mission statement, and goals can lead to efficient and effective provision of DSME. Documentation of an organizational structure that delineates...
channels of communication and represents institutional commitment to the educational entity is critical for success (38–42). According to the Joint Commission on Accreditation of Health Care Organizations (JCAHO) (26), this type of documentation is equally important for small and large health care organizations. Health care and business experts overwhelmingly agree that documentation of the process of providing services is a critical factor in clear communication and provides a solid basis from which to deliver quality diabetes education (22,26,33,35–37). In 2005, JACHC published the Joint Commission International Standards for Disease or Condition-Specific Care, which outlines national standards and performance measurements for diabetes and addresses diabetes self-management education as one of seven critical elements (26).

**Standard 2.** The DSME entity shall appoint an advisory group to promote quality. This group shall include representatives from the health professions, people with diabetes, the community, and other stakeholders.

Established and new systems (e.g., committees, governing bodies, advisory groups) provide a forum and a mechanism for activities that serve to guide and sustain the DSME entity (30,39–41). Broad participation of organization(s) and community stakeholders, including health professionals, people with diabetes, consumers, and other community interest groups, at the earliest possible moment in the development, ongoing planning, and outcomes evaluation process (22,26,33,35,36,41) can increase knowledge and skills about the local community and enhance collaborations and joint decision-making. The result is a DSME program that is patient-centered, more responsive to consumer-identified needs and the needs to the community, more culturally relevant, and of greater personal interest to consumers (43–50).

**Standard 3.** The DSME entity will determine the diabetes educational needs of the target population(s) and identify resources necessary to meet these needs.

Clarifying the target population and determining its self-management educational needs serve to focus resources and maximize health benefits (51–53). The assessment process should identify the educational needs of all individuals with diabetes, not just those who frequently attend clinical appointments (51). DSME is a critical component of diabetes treatment (2,34,35), yet the majority of individuals with diabetes do not receive any formal diabetes education (56,57). Thus, identification of access issues is an essential part of the assessment process (58). Demographic variables, such as ethnic background, age, formal educational level, reading ability, and barriers to participation in education, must also be considered to maximize the effectiveness of DSME for the target population (13–19,43–47,59–61).

**Standard 4.** A coordinator will be designated to oversee the planning, implementation, and evaluation of diabetes self-management education. The coordinator will have academic or experiential preparation in chronic disease care and education and in program management.

The role of the coordinator is essential to ensure that quality diabetes education is delivered through a coordinated and systematic process. As new and creative methods to deliver education are explored, the coordinator plays a pivotal role in ensuring accountability and continuity of the educational process (23,60–62). The individual serving as the coordinator will be most effective if there is familiarity with the lifelong process of managing a chronic disease (e.g., diabetes) and with program management.

**Process**

**Standard 5.** DSME will be provided by one or more instructors. The instructors will have recent educational and experiential preparation in education and diabetes management or will be a certified diabetes educator. The instructor(s) will obtain regular continuing education in the field of diabetes management and education. At least one of the instructors will be a registered nurse, dietitian, or pharmacist. A mechanism must be in place to ensure that the participant’s needs are met if those needs are outside the instructors’ scope of practice and expertise.

Diabetes education has traditionally been provided by nurses and dietitians. Nurses have been utilized most often as instructors in the delivery of formal DSME (2,3,5,63–67). With the emergence of medical nutrition therapy (66–70), registered dietitians became an integral part of the diabetes education team. In more recent years, the role of the diabetes educator has expanded to other disciplines, particularly pharmacists (73–79). Reviews comparing the effectiveness of different disciplines for education report mixed results (3,5,6). Generally, the literature favors current practice that utilizes the registered nurse, registered dietitian, and the registered pharmacist as the key primary instructors for diabetes education and members of the multidisciplinary team responsible for designing the curriculum and assisting in the delivery of DSME (1–7,77). In addition to registered nurses, registered dietitians, and pharmacists, a number of studies reflect the ever-changing and evolving health care environment and include other health professionals (e.g., a physician, behavioralist, exercise physiologist, ophthalmologist, optometrist, podiatrist) (48,80–84) and, more recently, lay health and community workers (85–91) and peers (92) to provide information, behavioral support, and links with the health care system as part of DSME.

Expert consensus supports the need for specialized diabetes and educational training beyond academic preparation for the primary instructors on the diabetes team (64,93–97). Certification as a diabetes educator by the National Certification Board for Diabetes Educators (NCBDE) is one way a health professional can demonstrate mastery of a specific body of knowledge, and this certification has become an accepted credential in the diabetes community (98). An additional credential that indicates specialized training beyond basic preparation is board certification in advanced Diabetes Management (BC-ADM) offered by the American Nurses Credentialing Center (ANCC), which is available for master’s prepared nurses, dietitians, and pharmacists (48,84,99).

DSME has been shown to be most effective when delivered by a multidisciplinary team with a comprehensive plan of care (7,31,52,100–102). Within the multidisciplinary team, team members work interdependently, consult with one another, and have shared objectives (7,103,104). The team should have a collective combination of expertise in the clinical care of diabetes, medical nutrition therapy, educational methodologies, teaching strategies, and the psychosocial and behavioral aspects of diabetes self-management. A referral mechanism should be in place to ensure that the individual with diabetes receives education from those with appropriate training and credentials. It is essential in this collaborative and integrated team approach that individuals with diabetes are viewed as leaders of their team and assume an active role in designing their educational experience (7,20,31,100–102,104).

**Standard 6.** A written curriculum reflecting current evidence and practice guidelines, with...
criteria for evaluating outcomes, will serve as the framework for the DSME entity. Assessed needs of the individual with pre-diabetes and diabetes will determine which of the content areas listed below are to be provided:

- Describing the diabetes disease process and treatment options
- Incorporating nutritional management into lifestyle
- Incorporating physical activity into lifestyle
- Using medication(s) safely and for maximum therapeutic effectiveness
- Monitoring blood glucose and other parameters and interpreting and using the results for self-management decision making
- Preventing, detecting, and treating acute complications
- Preventing detecting, and treating chronic complications
- Developing personal strategies to address psychosocial issues and concerns
- Developing personal strategies to promote health and behavior change

Multiple studies indicate the importance of individualizing education based on the assessment (1,56,68,131–135). The assessment includes information about the individual’s relevant medical history, age, cultural influences, health beliefs and attitudes, diabetes knowledge, self-management skills and behaviors, readiness to learn, health literacy level, physical limitations, family support, and financial status (10–17,19,131,136–138). The majority of these studies support the importance of attitudes and health beliefs in diabetes care outcomes (168,139,138). The assessment includes information about the individual’s relevant medical history, age, cultural influences, health beliefs and attitudes, diabetes knowledge, self-management skills and behaviors, readiness to learn, health literacy level, physical limitations, family support, and financial status (10–17,19,131,136–138). The majority of these studies support the importance of attitudes and health beliefs in diabetes care outcomes (168,139,138).

In addition, functional health literacy (FHL) level can affect patients’ self-management, communication with clinicians, and diabetes outcomes (140,141). Simple tools exist for measuring FHL as part of an overall assessment process (142–144).

Many people with diabetes experience problems due to medication costs, and asking patients about their ability to afford treatment is important (144). Co-morbid chronic illness (e.g., depression and chronic pain) as well as more general psychosocial problems can pose significant barriers to diabetes self-management (104,146–151); considering these issues in the assessment may lead to more effective planning (149–151).

Periodic reassessment determines attainment of the educational objectives or the need for additional and creative interventions and future reassessment (7,97,100,132). A variety of assessment modalities, including telephone follow-up and other information technologies (e.g., Web-based, automated phone calls), may augment face-to-face assessments (97,99).

While there is little direct evidence on the impact of documentation on patient outcomes, it is required to receive payment for services. In addition, documentation of patient encounters guides the educational process, provides evidence of communication among instructional staff, may prevent duplication of services, and provides information on adherence to guidelines (37,64,100,131,133). Providing information to other members of the patient’s health care team through documentation of educational objectives and personal behavioral goals increases the likelihood that all of the members will address these issues with the patient (37,98,133).

The use of evidence-based performance and outcome measures has been adopted by organizations and initiatives such as the Centers for Medicare and Medicaid Services (CMS), the National Committee for Quality Assurance (NCQA), the Diabetes Quality Improvement Project (DQIP), the Health Plan Employer Data and Information Set (HEDIS), the Veterans Administration Health System, and JCAHO (26,134).

Research suggests that the development of standardized procedures for documentation, training health professionals to document appropriately, and the use of structured standardized forms based on current practice guidelines can improve documentation and may ultimately improve quality of care (100,153–155).

Standard 8. A personalized follow-up plan for ongoing self-management support will be developed collaboratively by the participant and instructor(s). The patient’s outcomes and goals and the plan for ongoing self-management support will be communicated to the referring provider.

While DSME is necessary, it is not sufficient for patients to sustain a lifetime of diabetes self-care (35). Initial improvements in metabolic and other outcomes diminish after ~6 months (3). To sustain behavior at the level of self-management needed to effectively manage diabetes, most patients need ongoing diabetes self-management support (DSMS).

DSMS is defined as activities to assist the individual with diabetes to implement and sustain the ongoing behaviors needed to manage their illness. The type of support provided can include educational, psychosocial, or clinical (13,121–123).

A variety of strategies are available for
Standards and Review Criteria

providing DSMS both within and outside the DSME entity. Some patients benefit from working with a nurse case manager (7,20,98,157). Case management for DSMS can include reminders about needed follow-up care and tests, medication management, education, behavior goal-setting, and psychosocial support/ connection to community resources.

The effectiveness of providing DSMS through disease-management programs, trained peers and health community workers, community-based programs, use of technology, ongoing education and support groups, and medical nutrition therapy has also been established (7,13,89–92,101,123,138–159).

While the primary responsibility for diabetes education belongs to the DSME entity, patients benefit by receiving reinforcement of content and behavioral goals from their entire health care team (100). Additionally, many patients receive DSMS through their provider. Thus, communication is essential to ensure that patients receive the support they need.

Outcomes

Standard 9. The DSME entity will measure attainment of patient-defined goals and patient outcomes at regular intervals using appropriate measurement techniques to evaluate the effectiveness of the educational intervention.

In addition to program-defined goals and objectives (e.g., learning goals, metabolic, and other health outcomes), the DSME entity needs to assess each patient’s personal self-management goals and his/her progress toward those personal goals. The AADEd self-care behaviors provide a useful framework for assessment and documentation. Diabetes self-management behaviors include physical activity, healthy eating, medication taking, monitoring blood glucose, diabetes self-care related problem solving, reducing risks of acute and chronic complications, and psychosocial aspects of living with diabetes (112,160). Assessments of patient outcomes should occur at appropriate intervals. The interval depends on the outcome itself and the timeframe provided within the selected goals. For some areas, the indicators, measures, and timeframes may be based on guidelines from professional organizations or government agencies. In addition to assessing progress toward personal behavioral goals, a plan needs to be in place to communicate personal goals and progress to other team members.

The AADE Outcome Standards for Diabetes Education specify self-management behavior as the key outcome (112,160). Knowledge is an outcome to the degree that it is actionable (i.e., knowledge that can be translated into self-management behavior).

In turn, effective self-management is one (but not the only) contributor to longer-term, higher-order outcomes such as clinical status (e.g., control of glycemia, blood pressure, and cholesterol), health status (e.g., avoidance of complications), and subjective quality of life. Thus, patient self-management behaviors are at the core of the outcomes evaluation.

Standard 10. The DSME entity will measure the effectiveness of the education process and determine opportunities for improvement using a written continuous quality improvement plan that describes and documents a systematic review of the entities process and outcome data.

Diabetes education must be responsive to advances in knowledge, treatment strategies, educational strategies, psychosocial interventions, and the changing health care environment. Continuous quality improvement (CQI) is an iterative, planned process (161) that leads to improvement in the delivery of patient education (162). The CQI plan should define quality based on and consistent with the organization’s mission, vision, and strategic plan and include identifying and prioritizing improvement opportunities (163). Once improvement projects are identified and selected, the plan should incorporate timelines and important milestones including data collection, analysis, and presentation of results (163). Outcome measures indicate the result of a process (i.e., whether changes are actually leading to improvement), while process measures provide information about what caused those results (163–164). Process measures are often targeted to those processes that typically impact the most important outcomes. Measuring both process and outcomes helps to ensure that change is successful without causing additional problems in the system (164).

Acknowledgments—Work on this article was supported in part by grant nos. NIH5P60DK20572 and 1R18DK020233 from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.

The Task Force gratefully acknowledges the assistance and support of Paulina Duker, MPH, APRN-BC, CDE, and Nathaniel Clark, MD, CDE, of the American Diabetes Association; Lori Porter, MBA, RD, CAE, of the American Association of Diabetes Educators; and Karineh Kuller, MD, RD, BC-ADM, Past President, Health Care and Education of the American Diabetes Association; Malinda Duples, RN, MS, CDE, Past President of the American Association of Diabetes Educators; and Carole’ Mensing, RN, MA, CDE, for their insights and helpful suggestions.

We also gratefully acknowledge the work of the previous Task Force for the National Standards for DSME. Carole’ Mensing, RN, MA, CDE, Jackie Boucher, MS, RD, LD, CDE, Marjorie Cypress, MS, C-ANP, CDE, Katie Weinger, EdD, RN, Kathryn Mulcahy, MSN, RN, CDE, Patricia Banta, RN, MPH, CDE, Gwen Husey, MS, ARNP, CDE, Wendy Kopher, RN, C, CDE, HTP, Andrea Lasichak, MS, RD, CDE, Betsy Lamb, RN, MSN, Mavoumeen Mangan, RN, MS, ANP, C, CDE, Jan Norman, RD, CDE, Jon Tanga, BS, MS, RPH, Linda Yaak, MS, RD, LD, CDE, Kimberly Weldon, DMD, MS; and Cynthia Adams, PhD.

References

9. Roter DI, Hall JA, Merusca R, Nordstrom Port, RN, CDE, Cretin D, Svarstad B: Effectiveness of


26. Joint Commission on Accreditation of Healthcare Organizations: Joint Commission International Standards for Disease or Condition-Specific Care. 1st ed. Oakbrook Terrace, IL, Joint Accreditation on Healthcare Organizations, 2005


46. Hanis CL, Bridge, MA, Massachusetts Institute of Technology,

Diabetes Education, Volume 32, Supplement 1, January 2009

S91

Diabetes Education
Standards and Review Criteria

Julatory Care Manager 21:67–73, 1998


64. Davis ED: Role of the diabetes nurse educator in improving patient education. Diabetes Educ 16:360–403, 1990


111. Wikipedia. Curriculum definition.


128. Hayes JT, Boucher JL, Pronk NP, Gehlin
7.12  Diabetes Education

**Texas Diabetes Council:** Diabetes Tool Kit

### Standards and Review Criteria

This medication supplement guide is to provide health care professional with at-a-glance information on medications commonly used for people with diabetes. For complete prescribing information, please consult the medications package insert or the Physicians’ Desk Reference.
**Reviewers:**
Pamela Allweiss, MD, MPH, Consultant, Centers for Disease Control and Prevention, Division of Diabetes Translation, Faculty: University of Kentucky

James Cleeman, MD, National Heart, Lung and Blood Institute, National Institutes of Health
(review of sections B and C only)

Jeffrey Cutler, MD, National Heart, Lung and Blood Institute, National Institutes of Health
(review of sections B and C only)

Saul Malozowski, MD, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health

Amy Nicholas, Pharm D, CDE, University of Kentucky

Milissa Rock, RPh, CDE, CDM, The Diabetes Center, Old Saybrook, CT

Julio Rosenstock, MD, Dallas Diabetes and Endocrine Center, Dallas, TX
(review of Table 5 Incretins and Amylins only)

Robert Vigersky, MD, Director, Diabetes Institute, Walter Reed Health Care System, Professor: Uniformed Service University of Health Science

Donald Zettervall, RPH, CDE, CDM, The Diabetes Center, Old Saybrook, CT

**Credits and Acknowledgements**
The NDEP thanks the following members of the NDEP Pharmacy, Podiatry, Optometry and Dental (PPOD) professionals work group for their contributions to the NDEP publication Working Together to Manage Diabetes, English and Spanish PPOD patient education posters and this Medications Supplement:

Barbara Aung, D.P.M.
W. Lee Ball, Jr. O.D.
Norma Bowyer, O.D., M.P.H., F.A.O.O.
Joseph M. Caporusso, DPM
Caswell Evans, D.D.S., M.P.H.
Deborah Faucette, R.Ph.
JoAnn Gurenlian, RDH, PhD
Stuart T. Haines, Pharm.D., FCCP, FASHP, BCPS
Lawrence Harkless, D.P.M.

Mimi Hartman, MA, RD, CDE
Cynthia Heard, OD
Cynthia Hodge, D.M.D.
Tom Murray, Pharm.D.
Milissa A. Rock, RPh, CDE
Ross Taubman, D.P.M.
George W. Taylor, III, DMD, DrPH
Jaime R. Torres, DPM, MS

In addition, the following NDEP staff at CDC and NIH contributed to the review and revision of these materials:

Sabrina Harper MS,
NDEP CDC Assistant Director

Joanne Gallivan, MS, RD
NDEP NIH Program Director

Jane Kelly, MD
NDEP CDC Program Director

Betsy Rodriguez, MSN, CDE
NDEP CDC

Rachel Weinstein, MEd
NDEP NIH Deputy Director
### Table 1. Oral Agents to Treat Type 2 Diabetes

<table>
<thead>
<tr>
<th>Agent</th>
<th>Class</th>
<th>Primary Action</th>
<th>Typical Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glipizide (Glucoptil™)</td>
<td>Biguanide</td>
<td>Decreases hepatic glucose production and increases insulin secretion.</td>
<td>Initial: 1.25 mg/day, increased every 2 weeks.</td>
</tr>
<tr>
<td>Glimepiride (Amaryl™)</td>
<td>Thiazolidinedione</td>
<td>Decreases hepatic glucose production and increases insulin secretion.</td>
<td>Glimepiride: 1–8 mg/day; maximum, 8 mg/day</td>
</tr>
<tr>
<td>Nateglinide (Starlix™)</td>
<td>Meglitinide</td>
<td>Increases insulin release from pancreas.</td>
<td>New diagnosis or A1C &lt;8%, 0.5 mg; A1C &gt;8%, 1–2 mg; 15–30 min before each meal; increase weekly until results are obtained; maximum, 16 mg/day.</td>
</tr>
<tr>
<td>Tolbutamide (Orinase™)</td>
<td>Sulfonylurea (1st generation)</td>
<td>Increases insulin production in the pancreas.</td>
<td>Tolbutamide: 0.25–2.0 g/day in divided doses; maximum, 3 g/day; Tolazamide: 100–1,000 mg/day in divided doses; maximum, 1 g/day; Chlorpropamide: 100–500 mg/day twice a day; maximum, 750 mg/day.</td>
</tr>
<tr>
<td>Tolazamide (Tolinase™)</td>
<td>Sulfonylurea (2nd generation)</td>
<td>Increases insulin production in the pancreas.</td>
<td>Glipizide: 2.5–20.0 mg/once or twice a day; maximum, 40 mg/day; or XL: 2.5–10.0 mg/once or twice a day; maximum, 20 mg/day; Glimepiride: 1–8 mg/day; maximum, 8 mg/day.</td>
</tr>
<tr>
<td>Acarbose (Precose™)</td>
<td>Alpha-glucosidase inhibitor</td>
<td>Slows absorption of complex carbohydrate from GI tract.</td>
<td>Glimepiride: 1–8 mg/day; maximum, 8 mg/day.</td>
</tr>
<tr>
<td>Metformin (Fortamet™, Glumetza™, Glucophage™)</td>
<td>Biguanide</td>
<td>Primarily decreases hepatic glucose production. Minor increase in muscle glucose uptake which may improve insulin resistance.</td>
<td>500 mg/day twice a day with meals; increase by 500 mg every 1–3 wk, twice or three times a day; usually most effective at 2,000 mg/day; maximum, 2,550 mg/day.</td>
</tr>
<tr>
<td>Pioglitazone (Actos™)</td>
<td>Thiazolidinedione</td>
<td>Decreases insulin resistance, increasing glucose uptake, fat redistribution; minor decrease in hepatic glucose output; preserves β-cell function; decreases vascular inflammation.</td>
<td>Initially 15 or 30 mg/day; maximum with or without food 45 mg for monotherapy, 30 mg for combination therapy.</td>
</tr>
<tr>
<td>Gliclazide (Glyclor™)</td>
<td>Sulfonylurea and Biguanide</td>
<td>Decreases hepatic glucose production and increases insulin secretion.</td>
<td>Glimepiride: 1–8 mg/day; maximum, 8 mg/day.</td>
</tr>
<tr>
<td>Alogliptin (Bydureon™)</td>
<td>Thiazolidinedione and Biguanide</td>
<td>Decreases hepatic glucose production, increases glucose uptake, decreases insulin resistance, and preserves β-cell function.</td>
<td>Initial: 1.25/250 mg, 2 mg/500 mg, 5/500 mg/day; maximum dose: 20 mg glimepiride/2,000 mg metformin daily.</td>
</tr>
<tr>
<td>Avandamet™ (Raziglumetone and Metformin)</td>
<td>Thiazolidinedione and Biguanide</td>
<td>Decreases hepatic glucose production, increases glucose uptake, decreases insulin resistance, and preserves β-cell function.</td>
<td>1–8 mg/day; maximum, 8 mg/day.</td>
</tr>
<tr>
<td>Rosiglitazone and Metformin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>15 mg/500 mg, 15 mg/850 mg</td>
</tr>
</tbody>
</table>

**Combinations**

- **Glucovan™ (Glipizide and Metformin)**: Sulfonlylurea and Biguanide. Decreases hepatic glucose production and increases insulin secretion. Ratios of glipizide and metformin (in mg): 1.25/250, 2.5/500, 5/500. Initial: 1.25/250 once or twice a day, increased every 2 weeks. Average dose 7.5/1,500 mg/day. Maximum dose should not exceed 20 mg glipizide/2,000 mg metformin daily. |
- **Metaglip™ (Gliclazide and Metformin)**: Sulfonlylurea and Biguanide. Decreases hepatic glucose production and increases insulin secretion. Ratios of glipizide and metformin (in mg): 2.5/250, 5/500, 5/500. Initial: 2.5/250 once or twice a day, increased every 2 weeks. Maximum dose should not exceed 20 mg glipizide/2,000 mg metformin daily.
- **Avandamet™ (Raziglumetone and Metformin)**: Thiazolidinedione and Biguanide. Decreases hepatic glucose production, increases glucose uptake, decreases insulin resistance, and preserves β-cell function. Ratios of rosiglitazone and metformin: 1 mg/500 mg, 2 mg/500 mg, 4 mg/500 mg, 2 mg/1,000 mg, 4 mg/1,000 mg twice a day; dosage individualized based on current therapy. Maximum: 8 mg/2,000 mg per day. |
- **Actosplus Met™ (Pioglitazone and Metformin)**: Thiazolidinedione and Biguanide. Decreases hepatic glucose production, increases glucose uptake, decreases insulin. Ratios of pioglitazone and metformin: 15 mg/500 mg, 15 mg/850 mg. |
- **Avandaryl™ (Raziglumetone and Glimepiride)**: Thiazolidinedione and Sulfonylurea. Decreases insulin resistance and increases insulin secretion. Ratios of rosiglitazone and glimepiride: 4 mg/1 mg, 4 mg/2 mg. |

See Table 1 continuation on next page.

---

**Adapted from © 2006 The Diabetes Center, Old Saybrook, CT. Used with permission.**

- **A1C = glycated hemoglobin**
- **ALT = alanine aminotransferase**
- **CHF = congestive heart failure**
- **FPG = fasting plasma glucose**
- **GI = gastrointestinal**
- **XL = TZD = thiazolidinedione, CYP 450 = cytochrome P 450**
<table>
<thead>
<tr>
<th>Side Effects</th>
<th>Precautions</th>
<th>Critical Tests</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoglycemia, weight gain, hyperinsulinemia</td>
<td>Disulfiram reaction with alcohol</td>
<td>Chlorpropanide remains active for up to 60 hours. Use extreme caution with elderly patients or patients with hepatic or renal dysfunction.</td>
<td>Use of these agents is not recommended unless the patient has a well-established history of taking them. Second-generation sulfonylureas provide more predictable results with fewer side effects and more convenient dosing.</td>
</tr>
<tr>
<td>Hypoglycemia, weight gain, hyperinsulinemia</td>
<td>Glipizide (Glucotrol, Glucotrol XL™) Tolazamide (Tolinase™) Glucovance™</td>
<td></td>
<td>Glipizide is preferred with renal impairment. Does: &gt; 15 mg should be divided. Glimperide indicated for use with insulin. Shown to have some insulin-sensitizing effect.</td>
</tr>
<tr>
<td>Hypoglycemia, weight gain, hyperinsulinemia</td>
<td>Use with caution on patient with hepatic or renal impairment.</td>
<td></td>
<td>Patients should be instructed to take medication no more than 30 minutes prior to a meal. If meals are skipped or added, the medication should be skipped or added as well. Approved for use as monotherapy or in combination with TZD or metformin.</td>
</tr>
<tr>
<td>Minimal risk of hypoglycemia</td>
<td>Currently no contraindications available. Use with caution with moderate to severe hepatic disease.</td>
<td>Periodic evaluation of liver function tests.</td>
<td>Approved as monotherapy or in combination with metformin or TZD. Has only a 2-hour duration of action. If meals are skipped or added, the medication should be skipped or added as well.</td>
</tr>
<tr>
<td>Nausea, diarrhea, metallic taste, possible lactic acidosis</td>
<td>Due to increased risk of lactic acidosis, should not use if suspect frequent alcohol use, liver or kidney disease, or CHF.</td>
<td>Contraindicated if serum creatinine is: &gt;1.5 mg/dL in men or &gt;1.4 mg/dL women. Do not use if creatinine clearance is abnormal. Monitor hematological and renal function annually.</td>
<td>Especially beneficial in obese patients due to potential for weight loss, improved lipid profile, and lack of potential for hypoglycemia requiring supplemental carbohydrate intake. Discontinue for 48 hr after contrast dye procedures.</td>
</tr>
<tr>
<td>Minor weight increase of 3–6 lbs., edema</td>
<td>Should not be used in patients with CHF or hepatic disease. Can cause mild-to-moderate edema.</td>
<td>Avoid initiation if ALT &gt; 2.5X upper limit of normal. Measure ALT periodically. Discontinue if ALT &gt; 3X upper limit of normal.</td>
<td>Approved for use as monotherapy and in combination with metformin, sulfonylurea, or insulin. Less interactions associated with CYP-450.</td>
</tr>
<tr>
<td>Minor weight increase of 3–6 lbs., edema</td>
<td>Should not be used in patients with CHF or hepatic disease. Can cause mild-to-moderate edema.</td>
<td>Avoid initiation if ALT &gt; 2.5X upper limit of normal. Measure ALT periodically. Discontinue if ALT &gt; 3X upper limit of normal.</td>
<td>Avoid initiation if ALT &gt; 2.5X upper limit of normal. Measure ALT periodically. Discontinue if ALT &gt; 3X upper limit of normal.</td>
</tr>
<tr>
<td>Gas and bloating, sometimes diarrhea for both drugs</td>
<td>Should not be used if GI disorders are concurrent.</td>
<td>Avoid if serum creatinine is &gt; 2.0 mg/dL. Monitor serum transaminase every 3 months for 1st year of therapy.</td>
<td>Approved for use as monotherapy and in combination with metformin, sulfonylurea, or insulin. If used with hypoglycemic agents, such as sulfonylurea or insulin, must treat hypoglycemia with glucose not sucrose.</td>
</tr>
<tr>
<td>Hypoglycemia, weight gain, lactic acidosis</td>
<td>Should not be used if frequent alcohol use, liver or kidney disease, or CHF.</td>
<td>Same caveats as individual components.</td>
<td>Patients may frequently use 2 different dose tablets to attain desired daily dosage and results. Discontinue for 48 hr after procedure using contrast dye.</td>
</tr>
<tr>
<td>Hypoglycemia, weight gain, lactic acidosis</td>
<td>Should not be used if frequent alcohol use, liver or kidney disease, or CHF.</td>
<td>Same caveats as individual components.</td>
<td>Patients may frequently use 2 different dose tablets to attain desired daily dosage and results. Discontinue for 48 hr after procedure using contrast dye.</td>
</tr>
<tr>
<td>Edema, possible lactic acidosis</td>
<td>Should not be used if frequent alcohol use, liver or kidney disease, or CHF.</td>
<td>Same caveats as individual components.</td>
<td>Less expensive than using agents separately. Reported decrease in GI upset associated with metformin and weight increase associated with rosiglitazone. Discontinue for 48 hr after procedure using contrast dye.</td>
</tr>
<tr>
<td>Same caveats as individual components.</td>
<td>Same caveats as individual components.</td>
<td>Same caveats as individual components.</td>
<td>Same caveats as individual components.</td>
</tr>
<tr>
<td>Same caveats as individual components.</td>
<td>Same caveats as individual components.</td>
<td>Same caveats as individual components.</td>
<td>Same caveats as individual components.</td>
</tr>
</tbody>
</table>

* Agents in a class of medicines share mechanisms of action, require similar precautions, and generally have similar side effects. For proper usage, please read label. Agents should not be used in patients with type 1 diabetes.
### Diabetes Medications

#### Table 1 Continuation: Oral Agents to Treat Type 2 Diabetes

<table>
<thead>
<tr>
<th>Agent</th>
<th>Class</th>
<th>Primary Action</th>
<th>Typical Dose</th>
<th>Side Effects</th>
<th>Cautions</th>
<th>Critical Tests</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colestipol (Welchol)</td>
<td>Bile acid sequestrant</td>
<td>Slow complex carbohydrate absorption/lower fat flux through liver</td>
<td>625mg tablet, 6 tablets daily or 3 tablets BID</td>
<td>Constipation, Dyspepsia, Nausea</td>
<td>Bowel obstruction, Triglyceride &gt;500mg/dL, History of Pancreatitis</td>
<td>Lipid profile</td>
<td>May reduce absorption of: Phenytoin, warfarin, Levodopa. Other medicines should be moved 1 hour before colesvelam.</td>
</tr>
<tr>
<td>Sitagliptin/metformin Janumet</td>
<td>DPP-4 inhibitor</td>
<td>Reduce hepatic glucose production and lower post-prandial glucagon levels</td>
<td>Sitagliptin/metformin 50mg/500mg or 50mg/1000mg dosed BID Max: see individual components</td>
<td>See individual components</td>
<td>See individual components</td>
<td>See individual components</td>
<td>See individual components (Sitagliptin on Table 5)</td>
</tr>
<tr>
<td>Pioglitazone/glimepiride Duetact</td>
<td>Thiazolidinedione Sulfonylurea</td>
<td>Improve insulin resistance/increase pancreatic insulin secretion</td>
<td>Pioglitazone/glimepiride 30mg/2mg or 30mg/4mg Daily Max: 30mg/4mg Daily</td>
<td>See individual components</td>
<td>See individual components</td>
<td>See individual components</td>
<td>See individual components</td>
</tr>
</tbody>
</table>

#### Table 2. Glucose-Lowering Activity—Oral Diabetes Agent

<table>
<thead>
<tr>
<th>Medication</th>
<th>Blood Glucose Most Affected</th>
<th>Greatest Risk for Hypoglycemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sulfonylureas</td>
<td>Fasting and postprandial</td>
<td>Nocturnal, fasting, 4–6 hr after meals</td>
</tr>
<tr>
<td>Meglitinide or phenylalanine derivative</td>
<td>Postprandial</td>
<td>2–3 hr after meals</td>
</tr>
<tr>
<td>Biguanide</td>
<td>Postprandial</td>
<td>After exercise if prolonged and strenuous</td>
</tr>
<tr>
<td>Alpha-glucosidase inhibitor</td>
<td>Postprandial</td>
<td>None</td>
</tr>
<tr>
<td>Thiazolidinedione</td>
<td>Postprandial</td>
<td>None</td>
</tr>
<tr>
<td>Glucovance™</td>
<td>Fasting and postprandial</td>
<td>Nocturnal, fasting, 4–6 hr after meals</td>
</tr>
<tr>
<td>Metformin™</td>
<td>Fasting</td>
<td>Nocturnal, fasting 4–6 hr after meals</td>
</tr>
<tr>
<td>Avandamet™</td>
<td>Fasting and postprandial</td>
<td>After exercise if prolonged and strenuous</td>
</tr>
<tr>
<td>Actos Plus Met™</td>
<td>Fasting and postprandial</td>
<td>After exercise if prolonged and strenuous</td>
</tr>
<tr>
<td>Avandryl™</td>
<td>Fasting and postprandial</td>
<td>Nocturnal, fasting, 4–6 hr after meals</td>
</tr>
</tbody>
</table>

### Diabetes Medications

#### Table 2 Continuation: Glucose-Lowering Activity—Oral Diabetes Agent

<table>
<thead>
<tr>
<th>Medication</th>
<th>Blood Glucose Most Affected</th>
<th>Greatest Risk of Hypoglycemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin</td>
<td>Post-prandial</td>
<td>None</td>
</tr>
<tr>
<td>Colesvelam</td>
<td>Post-prandial</td>
<td>None</td>
</tr>
<tr>
<td>Sitagliptin/metformin</td>
<td>Fasting and post-prandial</td>
<td>None</td>
</tr>
<tr>
<td>Pioglitazone/glimepiride</td>
<td>Fasting and Post-prandial</td>
<td>Nocturnal, fasting, post-prandial</td>
</tr>
</tbody>
</table>

Adapted from © 2006 The Diabetes Center, Old Saybrook, CT. Used with permission. Testing frequency and times may vary based on individual assessment.
### Table 3. Important Insulin Information*

<table>
<thead>
<tr>
<th>Insulin Type</th>
<th>Onset</th>
<th>Peak (hours)</th>
<th>Effective Duration</th>
<th>Maximal Duration</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human Insulin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rapid Acting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lispro (Humalog™)</td>
<td>&lt;15 min</td>
<td>1–2 hr</td>
<td>2–4 hr</td>
<td>3–5 hr</td>
<td>Should be taken just prior to or just after eating.</td>
</tr>
<tr>
<td>Aspart (Novolog™)</td>
<td>&lt;15 min</td>
<td>1–3 hr</td>
<td>3–5 hr</td>
<td>4–6 hr</td>
<td>Should be taken just prior to or just after eating.</td>
</tr>
<tr>
<td>Glulisine (Apidra™)</td>
<td>&lt;15 min</td>
<td>0.5–1 hr</td>
<td>3 hr</td>
<td>3 hr</td>
<td>Should be taken just prior to or just after eating.</td>
</tr>
<tr>
<td>Short Acting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular (Novolin R™, Humulin R™)</td>
<td>0.5–1 hr</td>
<td>2–4 hr</td>
<td>3–5 hr</td>
<td>8 hr</td>
<td>Best if taken 30 min before a meal.</td>
</tr>
<tr>
<td>Intermediate Acting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lente (Novolin™, Humulin L™)</td>
<td>3–4 hr</td>
<td>4–12 hr</td>
<td>12–18 hr</td>
<td>16–20 hr</td>
<td>Limited supplies.</td>
</tr>
<tr>
<td>NPH (Novolin N™, Humulin N™)</td>
<td>2–4 hr</td>
<td>4–10 hr</td>
<td>10–16 hr</td>
<td>14–18 hr</td>
<td>Bedtime dosing minimizes nocturnal hypoglycemia.</td>
</tr>
<tr>
<td>Long Acting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin glargine (Lantus™ analog)</td>
<td>4–6 hr</td>
<td>None</td>
<td>24 hr</td>
<td>24 hr</td>
<td>Cannot be mixed with any other insulin. Stress site rotation and not to use same syringe used with other insulins. Not recommended for pre-filling syringes.</td>
</tr>
<tr>
<td>Detemir (Levemir™)</td>
<td>3–4 hr</td>
<td>50% in 3–4 hr, lasting up to 14 hr</td>
<td>5.7–23.2 hr</td>
<td>Dose dependent 5.7–23.2 hr</td>
<td>Cannot be mixed in same syringe with other insulins. Duration of action is dose dependent: 6 hrs (0.1U/kg), 12hrs (0.2U/kg), 20 hrs (0.4U/kg), 23 hrs (0.8U/kg and 1.6U/kg).</td>
</tr>
<tr>
<td>Pre-mixed Human</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Humalog 75/25 Novolog Mix™ 70/30</td>
<td>&lt;15 min</td>
<td>1–2 hr</td>
<td>10–16 hr</td>
<td>14–18 hr</td>
<td>75% NPL, 25% Lispro 70% NPH, 30% Aspart Should be taken just prior to or just after eating because of rapid onset. Caution because of name confusion with Humalog and Novolog.</td>
</tr>
<tr>
<td>Humulin M™ 70/30 Novolin™ 70/30</td>
<td>0.5–1 hr</td>
<td>2–10 hr</td>
<td>10–16 hr</td>
<td>14–18 hr</td>
<td>Humulin and Novolin are 70% NPH and 30% regular insulin.</td>
</tr>
</tbody>
</table>

**Adapted from © 2006 The Diabetes Center, Old Saybrook, CT. Used with permission.**

**Table 3 Continuation: Important Insulin Information**

**Discontinued Insulins:** All animal source insulins, Lente insulin, Ultralente insulin, Exubera inhaled

---

**TEXAS DIABETES COUNCIL**

2009 Additions to Diabetes Medications Supplement

---

**June 2009**
Table 4. Recommended Insulin Storage

<table>
<thead>
<tr>
<th>Insulin Type</th>
<th>Refrigerated (36°F - 46°F)</th>
<th>Room Temperature (59°F - 86°F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin Type</td>
<td>Opened</td>
<td>Unopened</td>
</tr>
<tr>
<td>Vial</td>
<td>28 days</td>
<td>Until expiration date</td>
</tr>
<tr>
<td>Humalog™, Novolog™, Humulin® N™, Novolin® N™, Apidra®</td>
<td>28 days</td>
<td>Until expiration date</td>
</tr>
<tr>
<td>Lantus® (10 mL)</td>
<td>28 days</td>
<td>Until expiration date</td>
</tr>
<tr>
<td>Detemir (Levemir™)</td>
<td>42 days</td>
<td>Until expiration date</td>
</tr>
<tr>
<td>Pens/Cartridges</td>
<td>Not in use</td>
<td>In use</td>
</tr>
<tr>
<td>Humalog™</td>
<td>Until expiration date</td>
<td>28 days</td>
</tr>
<tr>
<td>Humulin R™ (available in cartridge only)</td>
<td>Until expiration date</td>
<td>14 days</td>
</tr>
<tr>
<td>Humalog Mix 75/25™</td>
<td>Until expiration date</td>
<td>10 days</td>
</tr>
<tr>
<td>Novolin N™ (3-mL cartridge)</td>
<td>Until expiration date</td>
<td>10 days</td>
</tr>
<tr>
<td>Novolin 70/30™ (prefilled and 1.5-mL cartridge)</td>
<td>Until expiration date</td>
<td>7 days</td>
</tr>
<tr>
<td>Lantus® (10 mL)</td>
<td>Until expiration date</td>
<td>28 days</td>
</tr>
<tr>
<td>Detemir (Levemir™)</td>
<td>Until expiration date</td>
<td>42 days</td>
</tr>
<tr>
<td>Pens/Cartridges</td>
<td>Not in use</td>
<td>In use</td>
</tr>
<tr>
<td>Humalog™</td>
<td>Until expiration date</td>
<td>28 days</td>
</tr>
<tr>
<td>Humulin R™ (available in cartridge only)</td>
<td>Until expiration date</td>
<td>30 days</td>
</tr>
<tr>
<td>Humalog Mix 75/25™</td>
<td>Until expiration date</td>
<td>14 days</td>
</tr>
<tr>
<td>Novolin 70/30™ (prefilled and 1.5-mL cartridge)</td>
<td>Until expiration date</td>
<td>7 days</td>
</tr>
<tr>
<td>Novolin 70/30™ (3-mL cartridge)</td>
<td>Until expiration date</td>
<td>10 days</td>
</tr>
<tr>
<td>Detemir (Levemir™)</td>
<td>Until expiration date</td>
<td>42 days</td>
</tr>
<tr>
<td>Pens/Cartridges</td>
<td>Not in use</td>
<td>In use</td>
</tr>
<tr>
<td>Humalog™</td>
<td>Until expiration date</td>
<td>28 days</td>
</tr>
<tr>
<td>Humulin R™ (available in cartridge only)</td>
<td>Until expiration date</td>
<td>30 days</td>
</tr>
<tr>
<td>Humalog Mix 75/25™</td>
<td>Until expiration date</td>
<td>14 days</td>
</tr>
<tr>
<td>Novolin 70/30™ (prefilled and 1.5-mL cartridge)</td>
<td>Until expiration date</td>
<td>7 days</td>
</tr>
<tr>
<td>Novolin 70/30™ (3-mL cartridge)</td>
<td>Until expiration date</td>
<td>10 days</td>
</tr>
<tr>
<td>Detemir (Levemir™)</td>
<td>Until expiration date</td>
<td>42 days</td>
</tr>
<tr>
<td>Pens/Cartridges</td>
<td>Not in use</td>
<td>In use</td>
</tr>
<tr>
<td>Humalog™</td>
<td>Until expiration date</td>
<td>28 days</td>
</tr>
<tr>
<td>Humulin R™ (available in cartridge only)</td>
<td>Until expiration date</td>
<td>30 days</td>
</tr>
<tr>
<td>Humalog Mix 75/25™</td>
<td>Until expiration date</td>
<td>14 days</td>
</tr>
<tr>
<td>Novolin 70/30™ (prefilled and 1.5-mL cartridge)</td>
<td>Until expiration date</td>
<td>7 days</td>
</tr>
<tr>
<td>Novolin 70/30™ (3-mL cartridge)</td>
<td>Until expiration date</td>
<td>10 days</td>
</tr>
<tr>
<td>Detemir (Levemir™)</td>
<td>Until expiration date</td>
<td>42 days</td>
</tr>
<tr>
<td>Pens/Cartridges</td>
<td>Not in use</td>
<td>In use</td>
</tr>
<tr>
<td>Humalog™</td>
<td>Until expiration date</td>
<td>28 days</td>
</tr>
<tr>
<td>Humulin R™ (available in cartridge only)</td>
<td>Until expiration date</td>
<td>30 days</td>
</tr>
<tr>
<td>Humalog Mix 75/25™</td>
<td>Until expiration date</td>
<td>14 days</td>
</tr>
<tr>
<td>Novolin 70/30™ (prefilled and 1.5-mL cartridge)</td>
<td>Until expiration date</td>
<td>7 days</td>
</tr>
<tr>
<td>Novolin 70/30™ (3-mL cartridge)</td>
<td>Until expiration date</td>
<td>10 days</td>
</tr>
<tr>
<td>Detemir (Levemir™)</td>
<td>Until expiration date</td>
<td>42 days</td>
</tr>
</tbody>
</table>

TEXAS DIABETES COUNCIL
2009 Additions to Diabetes Medications Supplement

Table 4 Continuation: Recommended Insulin Storage

<table>
<thead>
<tr>
<th>Insulin Type</th>
<th>Refrigerated (36°F - 46°F)</th>
<th>Room Temperature (59°F - 86°F)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin Type</td>
<td>Opened</td>
<td>Unopened</td>
</tr>
<tr>
<td>Humalog Mix 50/50 Vial</td>
<td>28 days</td>
<td>Until expiration date</td>
</tr>
<tr>
<td>Humalog Mix 50/50 Pen device/cartridge</td>
<td>Do not refrigerate once opened.</td>
<td>Do not refrigerate once opened.</td>
</tr>
</tbody>
</table>

Adapted from © 2006 The Diabetes Center, Old Saybrook, CT. Used with permission. *Suggested, not clinically established
### Table 5. Incretins and Amylins

<table>
<thead>
<tr>
<th>Agent</th>
<th>Primary Action</th>
<th>How Supplied/Storage</th>
<th>Typical Dosage</th>
<th>Duration Action</th>
<th>Side Effects</th>
<th>Precautions</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exenatide (Byetta&lt;sup&gt;™&lt;/sup&gt;)</td>
<td>Decreases post-prandial glucose production. Delays gastric emptying.</td>
<td>250 mcg/mL - 5 mg/dose prefilled pen</td>
<td>5 mg BID subcutaneous for first 1 month, then 10 mg BID, injected within 30 minutes before morning and evening meal</td>
<td>Peak effects in approx 2 hours with maximal duration of 12 hours</td>
<td>Nausea and hypoglycemia most common, occasional vomiting, diarrhea, myalgia, headache.</td>
<td>Not for use in patients with Type 1 diabetes, severe renal disease or ESRD*, or severe GI disease.</td>
<td>Consider lowering dose of sulfonylurea to avoid hypoglycemia when starting. May reduce the rate of absorption of oral medication. Medications requiring threshold concentrations should be taken 1 hour prior to injection. Approved for use with sulfonylureas and/or metformin or in combination with a T2D&lt;sup&gt;™&lt;/sup&gt; alone or with metformin.</td>
</tr>
<tr>
<td>Pramlintide (Symlin&lt;sup&gt;™&lt;/sup&gt;)</td>
<td>Decreases post-prandial glucose production. Delays gastric emptying.</td>
<td>5 ml vials containing 6.6 mg/mL. Requires U-100 insulin syringe for injection if not in use: refrigerate until expiration date. If in use: room temperature Discord after 28 days.</td>
<td>Type 1 diabetes: 15-40 mcg starting with 15 mcg subcutaneously before meals of 30g or more carbohydrate. Type 2 diabetes: 60–120 mcg starting with 60 mcg subcutaneously before meals. Titrate as directed by prescriber.</td>
<td>Maximum effect in 20 minutes with rapid elimination. Maximum duration of 4 hours</td>
<td>Nausea and hypoglycemia most common. Doses are adjusted based on presentation of these side effects. Occasional vomiting, stomach pain, dizziness, hypoglycemia.</td>
<td>Indicated for insulin treated type 2 diabetes or for type 1 diabetes. Contraindicated in patients with hypoglycemia unawareness, gastroparesis. Or poor adherence. Should never be mixed with insulin and should be injected separately. Reduce insulin dose by 50% when starting.</td>
<td>Requires patient testing of blood sugars before and after meals. Frequent physician follow-up, and thorough understanding of how to adjust doses of insulin and pramlintide. May reduce the rate of absorption of orally administered medication. Medications requiring threshold concentrations should be taken 1 hour prior to injection.</td>
</tr>
<tr>
<td>Sitagliptin (Januvia&lt;sup&gt;™&lt;/sup&gt;)</td>
<td>DPP-4 inhibitor&lt;sup&gt;™&lt;/sup&gt; inhibits the DPP-4 enzyme that degrades GLP-1 and GIP resulting in 2-3 fold increased levels of these incretins. Increases insulin secretion in presence of elevated plasma glucose. Reduces post-meal glucagon secretion.</td>
<td>25mg, 50mg, 100mg tablets</td>
<td>100 mcg po qD Moderate renal insufficiency (GFR&lt;30 to &lt;50 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;): 50mcg/day</td>
<td>Approximately 24 hours</td>
<td>Low incidence of side effects including hypoglycemia or gastrointestinal symptoms. Headache, upper respiratory tract infection, nasopharyngitis.</td>
<td>Not for use in type 1 diabetes. Assessment of renal function is recommended prior to initiation and periodically thereafter.</td>
<td>May be used as monotherapy or in combination with metformin or T2Ds. Not associated with weight loss.</td>
</tr>
</tbody>
</table>

Adapted from © 2006 The Diabetes Center, Old Saybrook, CT. Used with permission. *DPP-4—dipeptidyl peptidase-4 GIP—glucose dependent insulinotropic polypeptide GLP—glucose like polypeptide

### Table 6. Hypoglycemia Treatment

<table>
<thead>
<tr>
<th>Agent</th>
<th>Primary Action</th>
<th>How Supplied/Storage</th>
<th>Typical Dosage</th>
<th>Duration Action</th>
<th>Side Effects</th>
<th>Precautions</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucagon</td>
<td>Converts liver glycogen to glucose.</td>
<td>1 mg vial with diluent, emergency kit, 1 mg vial with prefilled syringe of diluent. Before reconstitution, room temperature until expiration date. After reconstitution, may be stored up to 48 hours under refrigeration.</td>
<td>0.5–2 mg subcutaneously. 15 min, should be followed by carbohydrate snack.</td>
<td>Must be reconstituted prior to injection. Should be followed by carbohydrate snack and blood glucose testing every 15 minutes until glucose level returns to acceptable levels.</td>
<td>Occasional nausea and vomiting.</td>
<td>Patient should be instructed to teach colleagues, family, etc. to how to give injection. Only use if patient insensate or unable to eat or drink. All people taking insulin should receive a prescription for glucagon kit for emergency use.</td>
<td></td>
</tr>
</tbody>
</table>

Adapted from © 2006 The Diabetes Center, Old Saybrook, CT. Used with permission.

### Table 7. Recommended Control Measures

<table>
<thead>
<tr>
<th>Biochemical Index</th>
<th>Preprandial</th>
<th>Peak postprandial</th>
<th>A1C (ADA)*</th>
<th>Blood pressure</th>
<th>LDL</th>
<th>TG</th>
<th>HDL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goal</td>
<td>90–130 mg/dL</td>
<td>&lt; 180 mg/dL.</td>
<td>&lt; 7%</td>
<td>&lt; 130/80</td>
<td>&lt; 100</td>
<td>&lt; 150</td>
<td>&gt; 40</td>
</tr>
</tbody>
</table>

Adapted from © 2006 The Diabetes Center, Old Saybrook, CT. Used with permission. LDL — low density lipoprotein, TG — triglycerides, HDL — high density lipoprotein. *ADA—American Diabetes Association
### Medications to Lower High Blood Pressure*

<table>
<thead>
<tr>
<th>Category</th>
<th>Generic Name</th>
<th>Brand Name™</th>
<th>Minimum Daily Dose</th>
<th>Maximum Daily Dose</th>
<th>Special Considerations for class of drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Angiotensin-converting enzyme</strong></td>
<td>benazepril</td>
<td>Lotensin™</td>
<td>10 mg QD</td>
<td>40 mg QD or divided</td>
<td>May cause cough.</td>
</tr>
<tr>
<td><strong>inhibitors</strong></td>
<td>captopril</td>
<td>Capoten™</td>
<td>25 mg divided dose</td>
<td>100 mg divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>enalapril</td>
<td>Vasotec™</td>
<td>5 mg QD</td>
<td>40 mg QD or divided</td>
<td></td>
</tr>
<tr>
<td></td>
<td>losartan</td>
<td>Hyzaar™</td>
<td>10 mg QD</td>
<td>40 mg QD or divided</td>
<td></td>
</tr>
<tr>
<td></td>
<td>moexipril</td>
<td>Univasc™</td>
<td>7.5 mg QD</td>
<td>30 mg QD or divided</td>
<td></td>
</tr>
<tr>
<td></td>
<td>quinapril</td>
<td>Accupril™</td>
<td>10 mg QD</td>
<td>80 mg QD or divided</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ramipril</td>
<td>Altace™</td>
<td>2.5 mg QD</td>
<td>20 mg QD or divided</td>
<td></td>
</tr>
<tr>
<td><strong>Angiotensin II</strong></td>
<td>trandolapril</td>
<td>Mavik™</td>
<td>1 mg QD</td>
<td>4 mg QD</td>
<td>May cause dizziness and upset stomach.</td>
</tr>
<tr>
<td><strong>receptor blockers</strong></td>
<td>candesartan</td>
<td>Atacand™</td>
<td>8 mg QD</td>
<td>32 mg QD or divided</td>
<td></td>
</tr>
<tr>
<td></td>
<td>eprosartan</td>
<td>Teveten™</td>
<td>400 mg QD</td>
<td>800 mg QD or divided</td>
<td></td>
</tr>
<tr>
<td></td>
<td>irbesartan</td>
<td>Avapro™</td>
<td>150 mg QD</td>
<td>300 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>losartan</td>
<td>Cazzar™</td>
<td>25 mg QD</td>
<td>100 mg QD or divided</td>
<td></td>
</tr>
<tr>
<td></td>
<td>olmesartan</td>
<td>Benicar™</td>
<td>20 mg QD</td>
<td>40 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>telmisartan</td>
<td>Micardis™</td>
<td>20 mg QD</td>
<td>80 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>valsartan</td>
<td>Diovan™</td>
<td>80 mg QD</td>
<td>320 mg QD</td>
<td></td>
</tr>
<tr>
<td><strong>Calcium channel</strong></td>
<td>amlodipine</td>
<td>Norvasc™</td>
<td>2.5 mg QD</td>
<td>10 mg QD</td>
<td>May cause constipation, dizziness, upset stomach, and flushing.</td>
</tr>
<tr>
<td><strong>blockers</strong></td>
<td>diltiazem</td>
<td>Cardizem LA™</td>
<td>120 mg QD</td>
<td>540 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>diltiazem</td>
<td>Cardizem CD™</td>
<td>180 mg QD</td>
<td>420 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>diltiazem</td>
<td>Dilace XR™</td>
<td>180 mg QD</td>
<td>420 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>diltiazem</td>
<td>Tiazac™</td>
<td>180 mg QD</td>
<td>420 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>felodipine</td>
<td>Plendil™</td>
<td>2.5 mg QD</td>
<td>20 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>isradipine</td>
<td>DynaCirc CR™</td>
<td>2.5 mg QD</td>
<td>10 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>nifedipine</td>
<td>Adalat CC™</td>
<td>30 mg QD</td>
<td>60 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>nifedipine</td>
<td>Procardia XL™</td>
<td>30 mg QD</td>
<td>60 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>nisoldipine</td>
<td>Solar™</td>
<td>10 mg QD</td>
<td>40 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>verapamil</td>
<td>Calan™</td>
<td>80 mg QD or divided dose</td>
<td>320 mg QD or divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>verapamil</td>
<td>Calan SR™</td>
<td>120 mg QD</td>
<td>480 mg divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>verapamil</td>
<td>Covera HS™</td>
<td>120 mg QD</td>
<td>360 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>verapamil</td>
<td>Isoptin™</td>
<td>80 mg QD or divided dose</td>
<td>320 mg QD or divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>verapamil</td>
<td>Isoptin SR™</td>
<td>120 mg QD</td>
<td>480 mg QD or divided</td>
<td></td>
</tr>
<tr>
<td></td>
<td>verapamil</td>
<td>Verelan™</td>
<td>80 mg QD or divided dose</td>
<td>320 mg QD or divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>verapamil</td>
<td>Verelan PM™</td>
<td>120 mg QD</td>
<td>360 mg QD</td>
<td></td>
</tr>
<tr>
<td><strong>Thiazides and</strong></td>
<td>bedoniflumethiazide</td>
<td>Naturetin™</td>
<td>2.5 mg QD</td>
<td>20 mg QD</td>
<td>May increase blood glucose concentrations.</td>
</tr>
<tr>
<td>related diuretics**</td>
<td>chlorothiazide</td>
<td>Diuril™</td>
<td>125 mg QD</td>
<td>500 mg QD or divided</td>
<td>Take in morning to minimize diuretic effect at night.</td>
</tr>
<tr>
<td></td>
<td>chlorthalidone</td>
<td>Hygroton™</td>
<td>12.5 mg QD</td>
<td>25 mg QD</td>
<td>May cause low potassium, need to monitor level.</td>
</tr>
<tr>
<td></td>
<td>hydrochlorothiazide</td>
<td>HydroDIURIL™</td>
<td>12.5 mg QD</td>
<td>25 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>hydrochlorothiazide</td>
<td>Micardid™</td>
<td>12.5 mg QD</td>
<td>50 mg QD or divided</td>
<td></td>
</tr>
<tr>
<td></td>
<td>indapamide</td>
<td>Lopressor™</td>
<td>1.25 mg QD</td>
<td>2.5 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>methyldopa</td>
<td>Enalapril™</td>
<td>2.5 mg QD</td>
<td>5 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>methyldopa</td>
<td>Monoject™</td>
<td>0.5 mg QD</td>
<td>1.0 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>metolazone</td>
<td>Micronid™</td>
<td>2.5 mg QD</td>
<td>5 mg QD</td>
<td></td>
</tr>
</tbody>
</table>

* Agents in a class of medicines share mechanisms of action, require similar precautions and generally have similar side effects.

CC= extended release  XL=extended release  SR=sustained release  CR=controlled release  CD=extended release  XR=extended release
PM=extended release, controlled onset  HS=extended release, controlled onset  Dosages based on JNC7 usual dose range.
## Medications to Lower High Blood Pressure* (continued)

<table>
<thead>
<tr>
<th>Category</th>
<th>Generic Name</th>
<th>Brand Name™</th>
<th>Minimum Daily Dose</th>
<th>Maximum Daily Dose</th>
<th>Special Considerations for class of drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loop diuretics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loop diuretics</td>
<td>bumetanide</td>
<td>Bumex™</td>
<td>0.5 mg QD</td>
<td>2 mg QD or divided</td>
<td>May cause low potassium. Need blood test to monitor level. (Parenteral drug available) May cause photosensitivity; sunscreen recommended.</td>
</tr>
<tr>
<td></td>
<td>ethacrynic acid</td>
<td>Edecrin™</td>
<td>25 mg QD</td>
<td>200 mg divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>furosemide</td>
<td>Lasix™</td>
<td>20 mg QD</td>
<td>80 mg QD or divided</td>
<td></td>
</tr>
<tr>
<td></td>
<td>torsemide</td>
<td>Demadex™</td>
<td>2.5 mg QD</td>
<td>10 mg QD</td>
<td></td>
</tr>
<tr>
<td>Potassium-sparing diuretics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Do not use potassium or salt substitutes without consulting physician. Need to monitor potassium level.</td>
</tr>
<tr>
<td></td>
<td>spironolactone</td>
<td>Aldactone™</td>
<td>25 mg QD</td>
<td>50 mg divided dose</td>
<td></td>
</tr>
<tr>
<td>Aldosterone receptor blockers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>eplerenone</td>
<td>Inspra™</td>
<td>50 mg QD</td>
<td>100 mg divided dose</td>
<td></td>
</tr>
<tr>
<td>β-blockers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>acebutolol</td>
<td>Sectral™</td>
<td>200 mg QD</td>
<td>800 mg divided dose</td>
<td>Intrinsic sympathomimetic activity. May alter blood glucose, may mask signs of low blood.</td>
</tr>
<tr>
<td></td>
<td>atenolol</td>
<td>Tenormin™</td>
<td>25 mg QD</td>
<td>100 mg QD</td>
<td>Call physician for slow heart rate (&lt;60), confusion, or swelling of feet or legs.</td>
</tr>
<tr>
<td></td>
<td>betaxolol</td>
<td>Kerlone™</td>
<td>5 mg QD</td>
<td>20 mg QD</td>
<td>Can cause claudication. Do not discontinue abruptly.</td>
</tr>
<tr>
<td></td>
<td>betaxolol</td>
<td>Kerlone™</td>
<td>5 mg QD</td>
<td>20 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>bisoprolol</td>
<td>Zebeta™</td>
<td>2.5 mg QD</td>
<td>10 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>carvedilol</td>
<td>Coreg™</td>
<td>12.5 mg divided dose</td>
<td>50 mg divided dose</td>
<td>May mask signs of low blood glucose levels. Take with food to avoid stomach upset.</td>
</tr>
<tr>
<td></td>
<td>carvedilol</td>
<td>Coreg™</td>
<td>12.5 mg divided dose</td>
<td>50 mg divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>labetalol</td>
<td>Normodyne™</td>
<td>200 mg divided dose</td>
<td>800 mg divided dose</td>
<td>May cause headaches, fluid retention, or fast heart rate.</td>
</tr>
<tr>
<td></td>
<td>labetalol</td>
<td>Normodyne™</td>
<td>200 mg divided dose</td>
<td>800 mg divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>metoprolol</td>
<td>Lopressor™</td>
<td>50 mg QD</td>
<td>100 mg QD or divided</td>
<td></td>
</tr>
<tr>
<td></td>
<td>metoprolol</td>
<td>Lopressor™</td>
<td>50 mg QD</td>
<td>100 mg QD or divided</td>
<td></td>
</tr>
<tr>
<td></td>
<td>nadolol</td>
<td>Corgard™</td>
<td>40 mg QD</td>
<td>120 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>penbutolol</td>
<td>Levatol™</td>
<td>10 mg QD</td>
<td>40 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>propranolol</td>
<td>Inderal™</td>
<td>40 mg divided dose</td>
<td>160 mg divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>propranolol</td>
<td>Inderal™</td>
<td>40 mg divided dose</td>
<td>160 mg divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>timolol</td>
<td>Blocadren™</td>
<td>20 mg divided dose</td>
<td>40 mg divided dose</td>
<td></td>
</tr>
<tr>
<td>α-blockers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>doxazosin</td>
<td>Cardura™</td>
<td>1 mg QD</td>
<td>16 mg QD</td>
<td>To prevent dizziness, avoid standing up suddenly, especially with the first few doses.</td>
</tr>
<tr>
<td></td>
<td>prazosin</td>
<td>Minipress™</td>
<td>2 mg in divided dose</td>
<td>20 mg divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>terazosin</td>
<td>Hytrin™</td>
<td>1 mg QD</td>
<td>20 mg QD</td>
<td></td>
</tr>
<tr>
<td>Combined α- and β-blockers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>carvedilol</td>
<td>Coreg™</td>
<td>12.5 mg divided dose</td>
<td>50 mg divided dose</td>
<td>May mask signs of low blood glucose levels. Take with food to avoid stomach upset.</td>
</tr>
<tr>
<td></td>
<td>labetalol</td>
<td>Normodyne™</td>
<td>200 mg divided dose</td>
<td>800 mg divided dose</td>
<td>May cause headaches, fluid retention, or fast heart rate.</td>
</tr>
<tr>
<td></td>
<td>labetalol</td>
<td>Normodyne™</td>
<td>200 mg divided dose</td>
<td>800 mg divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>metoprolol</td>
<td>Lopressor™</td>
<td>50 mg QD</td>
<td>100 mg QD or divided</td>
<td></td>
</tr>
<tr>
<td></td>
<td>metoprolol</td>
<td>Lopressor™</td>
<td>50 mg QD</td>
<td>100 mg QD or divided</td>
<td></td>
</tr>
<tr>
<td></td>
<td>nadolol</td>
<td>Corgard™</td>
<td>40 mg QD</td>
<td>120 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>penbutolol</td>
<td>Levatol™</td>
<td>10 mg QD</td>
<td>40 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>propranolol</td>
<td>Inderal™</td>
<td>40 mg divided dose</td>
<td>160 mg divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>propranolol</td>
<td>Inderal™</td>
<td>40 mg divided dose</td>
<td>160 mg divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>timolol</td>
<td>Blocadren™</td>
<td>20 mg divided dose</td>
<td>40 mg divided dose</td>
<td></td>
</tr>
<tr>
<td>Direct vasodilators</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>hydralazine</td>
<td>Apresoline™</td>
<td>25 mg QD</td>
<td>100 mg divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>mepidine</td>
<td>Lanthine™</td>
<td>2.5 mg QD</td>
<td>80 mg divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>mepidine</td>
<td>Lanthine™</td>
<td>2.5 mg QD</td>
<td>80 mg divided dose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>nifedipine</td>
<td>Adalat™</td>
<td>20 mg divided dose</td>
<td>1,000 mg divided dose</td>
<td>Do not discontinue drug suddenly without consulting physician.</td>
</tr>
<tr>
<td></td>
<td>guanfacine</td>
<td>Tenex™</td>
<td>0.5 mg QD</td>
<td>2 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>guanfacine</td>
<td>Tenex™</td>
<td>0.5 mg QD</td>
<td>2 mg QD</td>
<td></td>
</tr>
<tr>
<td>Peripheral Anti-adrenergics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>guanadrel</td>
<td>Hyfrorel™</td>
<td>10 mg in divided dose</td>
<td>75 mg divided dose</td>
<td>May cause dizziness, nasal congestion, and depression.</td>
</tr>
<tr>
<td></td>
<td>guanethidine</td>
<td>Ioxilan™</td>
<td>10 mg QD</td>
<td>50 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>guanethidine</td>
<td>Ioxilan™</td>
<td>10 mg QD</td>
<td>50 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>reserpine</td>
<td>Benserin™</td>
<td>0.1 mg divided dose</td>
<td>0.25 mg divided dose</td>
<td></td>
</tr>
</tbody>
</table>

* Agents in a class of medicines share mechanisms of action, require similar precautions and generally have similar side effects.

**Note:** There are many combination medications for the control of blood pressure. The indications and caveats are the same for each individual component.

### For all anti-hypertensives:
- Ask pharmacist before using OTC products.
- Monitor blood pressure regularly.
- To prevent dizziness, advise patient to stand up slowly. If dizziness persists, refer to health care provider.

### Information about high blood pressure can be found at the following Web sites:
- Drugs used to treat high blood pressure: [http://www.nhlbi.nih.gov/guidelines/hypertension/express.pdf](http://www.nhlbi.nih.gov/guidelines/hypertension/express.pdf)
## SECTION C

### Medications for the Treatment of Dyslipidemia

<table>
<thead>
<tr>
<th>Category</th>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Minimum Daily Dose</th>
<th>Maximum Daily Dose</th>
<th>Special Considerations for class of drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>HMG-CoA reductase inhibitors (statins)</td>
<td>atorvastatin</td>
<td>Lipitor™</td>
<td>10 mg QD</td>
<td>80 mg in divided doses</td>
<td>Main action: Lowers LDL (“bad”) cholesterol. Also lowers TG and moderately raises HDL. Have blood tests for liver enzyme concentrations. Notify physician if muscle aches or weakness develops. Use caution if combined with fibric acid derivatives due to the increased risk of rhabdomyolysis.</td>
</tr>
<tr>
<td></td>
<td>fluvastatin</td>
<td>Lescol™</td>
<td>20 mg QD</td>
<td>80 mg in divided doses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>fluvastatin</td>
<td>Lescol XL™</td>
<td>80 mg QD</td>
<td>80 mg in divided doses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>lovastatin</td>
<td>Mevacor™</td>
<td>10 mg QD</td>
<td>80 mg in divided doses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>lovastatin (extended-release)</td>
<td>Alcort™</td>
<td>20 mg QD</td>
<td>60 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>pravastatin</td>
<td>Pravachol™</td>
<td>10 mg QD</td>
<td>80 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>rosvastatin</td>
<td>Crestor™</td>
<td>5 mg QD</td>
<td>40 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>simvastatin</td>
<td>Zocor™</td>
<td>5 mg QD</td>
<td>80 mg in divided doses</td>
<td></td>
</tr>
<tr>
<td>Cholesterol absorption inhibitors</td>
<td>ezetimibe</td>
<td>Zetia™</td>
<td>10 mg QD</td>
<td>10 mg QD</td>
<td>Main action: Lowers LDL cholesterol; inhibits absorption of cholesterol. If used with a statin, take together. If used with bile acid sequestrant, ezetimibe should be taken 2 hr before or 4 hr after bile acid sequestrant.</td>
</tr>
<tr>
<td>Nicotinic acid (nicacin)</td>
<td>nicotinic acid (extended release)</td>
<td>Niagen™</td>
<td>50–100 mg QD</td>
<td>2,000 mg QD</td>
<td>Main action: Lowers LDL cholesterol increases HDL (&quot;good&quot;) cholesterol, lowers triglycerides. Take with food. May cause flushing. May increase blood pressure levels. Have blood tests for liver enzyme concentrations. Long-acting forms may be more likely to cause liver malfunction.</td>
</tr>
<tr>
<td>Nicotinic acid (nicacin)</td>
<td>nicotinic acid</td>
<td>Zetia™</td>
<td>250 mg/day QD</td>
<td>Titrated up to 1500mg therapeutic dose in 3 divided doses. Maximum dose = 3000mg</td>
<td></td>
</tr>
<tr>
<td>Lipid combinations</td>
<td>lovastatin-niacin</td>
<td>Advicor™</td>
<td>20 mg/500 mg QD</td>
<td>40 mg/2,000 mg QD</td>
<td>Main Action: Reduces LDL, TC, and TG and increases HDL due to the individual actions of niacin and lovastatin.</td>
</tr>
<tr>
<td></td>
<td>simvastatin-ezetimibe</td>
<td>Vytorin™</td>
<td>10 mg/10 mg QD</td>
<td>80 mg/10 mg QD</td>
<td>Main Action: Reduces LDL cholesterol.</td>
</tr>
<tr>
<td></td>
<td>Amiodipine+atorvastatin</td>
<td>Caduet™</td>
<td>2.5mg/10mg QD</td>
<td>10 mg/80 mg QD</td>
<td>Blood Pressure medication (Calcium channel blocker (see Blood Pressure med chart)+ lipid (statin) medication. Some comments as individual</td>
</tr>
<tr>
<td>Fabric acid derivatives</td>
<td>fenofibrate</td>
<td>Tricor™</td>
<td>48 mg QD</td>
<td>145 mg QD</td>
<td>Main action: Lowers triglycerides, increases HDL cholesterol. Perform blood tests for liver enzyme concentrations. Adjust dose based on age and renal impairment. Notify physician if muscle aches or weakness develops.</td>
</tr>
<tr>
<td></td>
<td>fenofibrate</td>
<td>Lipid®</td>
<td>67 mg QD</td>
<td>200 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>fenofibrate</td>
<td>Triglide™</td>
<td>50 mg QD</td>
<td>160 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>fenofibrate</td>
<td>Antara™</td>
<td>63 mg QD</td>
<td>130 mg QD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>gemfibrozil</td>
<td>Lipid®</td>
<td>1,000 mg BID</td>
<td>2,000 mg BID</td>
<td></td>
</tr>
<tr>
<td>Bile acid sequestrants</td>
<td>cholestyramine</td>
<td>LoCHOLEST™</td>
<td>4 g QD</td>
<td>24 g in divided doses</td>
<td>Main action: Lowers LDL cholesterol. May cause constipation and stomach upset. May need to be taken at a different time than other medications to avoid drug interactions. May increase triglycerides blood concentrations. Can be combined with other agents such as statins.</td>
</tr>
<tr>
<td></td>
<td>cholestyramine light</td>
<td>LoCHOLEST Light™</td>
<td>4 g QD</td>
<td>24 g in divided doses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>cholestyramine</td>
<td>Questran™</td>
<td>4 g QD</td>
<td>24 g in divided doses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>cholestyramine light</td>
<td>Questran Light™</td>
<td>4 g QD</td>
<td>24 g in divided doses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>cholestyramine</td>
<td>Primidol™</td>
<td>4 g QD</td>
<td>24 g in divided doses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>colesu坏了</td>
<td>Colesu坏了™</td>
<td>2g QD or BID</td>
<td>6g QD or BID</td>
<td></td>
</tr>
</tbody>
</table>

HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A  LDL = low-density lipoprotein  HDL = high-density lipoprotein  TC = total cholesterol  TG = plasma triglycerides  generic = generic drug manufacturers
Resources for Individuals with Diabetes

Note: Resources for Individuals with Diabetes is updated routinely. The most recent version can be accessed on the Texas Diabetes Council web site at www.texasdiabetescouncil.org.

Statewide Organizations

Children’s Health Insurance Program in Texas (CHIP)/Children’s Medicaid
1-800-647-6558, 1-877-543-7669
fax: 1-877-542-5951
www.chipmedicaid.org
Comprehensive health insurance for children (newborn through age 18) in families that earn too much to qualify for Medicaid but likely cannot afford to buy health insurance.

Medicaid
Texas Department of Human Services
Statewide: 1-800-252-8263
www.hhsc.state.tx.us/medicaid/index.html
Eligibility is based on financial income.

Children with Special Health Care Needs (CSHCN, formerly CIDC)
Phones: 1-800-252-8023, or 1-800-422-2956 (Family Health Services)
Fax: 512-458-7417
www.dshs.state.tx.us/cshcn
Children with Special Health Care Needs (formerly CIDC) provides state-funded assistance for children with type 1 and type 2 diabetes for services not covered by Medicaid, CHIP, private insurance or third party payors.

Texas Diabetes Prevention & Control Program/Council
Texas Department of State Health Services
P.O. Box 149347, Mail Code 1965
Austin, Texas 78714-9347
(512) 458-7490, 1-888-963-7111 ext. 7490
www.texasdiabetescouncil.org
The Texas Diabetes Council was established by the Texas Legislature in 1983 and works with private and public organizations to promote diabetes prevention and awareness of quality care. The Council develops, implements and monitors a state plan for diabetes prevention and control. FREE educational materials are available to order online.

Texas Department of State Health Services Audiovisual Library
P.O. Box 149347, Mail Code 1975
Austin, TX 78714-9347
1-888-963-7111 ext. 7260
TDD: 512-458-7708
www.dshs.state.tx.us/avlib/default.shtm
Offers free loan of audiovisual materials to Texas residents on a number of health and safety topics.
HHSC (Health and Human Services Commission) Office of the Ombudsman
1-877-787-8999
Fax: 512-491-1067
TDD Hotline 888-425-6889 or 512-438-3087 (not toll free)
The Office of the Ombudsman was created to assist the public with health and human services-related complaints or issues.

National Organizations

American Association of Diabetes Educators
200 W. Madison Street, Suite 800
Chicago, Illinois 60606
1-800-338-3633 (general inquiries)
1-800-832-6874 or www.mydiabetespartner.org for diabetes educators in your area
www.diabeteseducator.org
email: aade@aadenet.org

American Diabetes Association
1660 Duke Street
Alexandria, Virginia 22314
1-800-806-7801 (membership)
1-800-342-2383
1-800-232-6733 to order publications
www.diabetes.org

American Dietetic Association
120 South Riverside Plaza, Suite 2000
Chicago, Illinois 60606-6995
1-800-877-1600
Consumer Nutrition Hotline:
1-800-366-1655 (Spanish available) for a list of registered dietitians in your area
www.eatright.org

Centers for Disease Control and Prevention Division of Diabetes Translation
4770 Buford Highway, NE, Mailstop K-10
Atlanta, Georgia 30341-3717
1-800-232-4636
1-770-488-5000/Fax: 1-770-488-5966
TTY: 1-888-232-6348
1-877-CDC-DIAB (232-3422)
www.cdc.gov/diabetes
Joslin Diabetes Center
One Joslin Place
Boston, MA 02215
617-732-2400
www.joslin.org

Juvenile Diabetes Research Foundation International (JDRF)
120 Wall St., 19th Floor
New York, New York 10005-4001
1-800-533-2873 (JDF-CURE)
www.jdf.org
email: info@jdf.org

Medic Alert Foundation International
2323 Colorado Avenue
Turlock, California 95382
1-800-ID-ALERT (432-5378), or 1-888-633-4298
www.medicalert.org

Diabetes Research and Wellness Foundation
5151 Wisconsin Ave., NW
Suite 420
Washington, D.C. 20016
www.diabeteswellness.net

National Diabetes Information Clearinghouse
1 Information Way
Bethesda, Maryland 20892-3560
(301) 654-3327
1-800-860-8747
ndic@info.niddk.nih.gov
www.niddk.nih.gov

National Diabetes Education Program
One Diabetes Way
Bethesda, MD 20814-9692
1-800-438-5383
Five web addresses:
www.cdc.gov/diabetes/ndep home page
www.ndep.nih.gov for publications, audiovisual resources & publications
www.diabetesatwork.org for business and managed care organizations
www.betterdiabetescare.nih.gov for changes in health systems
www.cdc.gov/podcasts for podcast viewing

American Diabetes Association, American Dietetic Association, and the other organizations listed above have educational publications and audiovisual materials available, some at no cost. The list of other materials is only a sampling of diabetes education materials. The public library, local health department, local hospital and heart association are also sources for information.
Patient Magazines/Print

Diabetes Digest
5 South Myrtle Ave.
Spring Valley, NY 10977
845-426-7612
fax: 845-426-7512

Diabetes Forecast
www.forecast.diabetes.org

Diabetes Health
6 School St.
Suite 160
Fairfax, CA 94930
1-800-234-1218
fax: 415-258-2822
www.diabeteshealth.com

Diabetes Interview (monthly)
P.O. Box 668
Fairfax, CA 94978-0668
1-800-488-8468
Fax 1-800-559-0031

Diabetes Self-Management
P.O. Box 51125
Boulder, CO 80323-1125

Diabetes Wellness Letter
DRWF, P.O. 231
Shrub Oak, NY 10588

Practical Diabetology
150 22nd Street
New York, NY 10011

Voice of the Diabetic
Free upon Request
811 Cherry Street, Ste. 309
Columbia, MO 65201-4892
Patient Magazines/Online

Children with Diabetes
www.childrenwithdiabetes.com
Helps kids with diabetes and their families learn about diabetes, meet people with diabetes, and help others with diabetes.

Diabetic Gourmet
www.diabeticgourmet.com
Online magazine dedicated to healthy eating, diabetes, and diabetes-related health issues, with news, recipes, articles, forums, tools, and more.

Diabetic Lifestyle Online Magazine
Includes recipes, menus, medical updates, and practical information on managing diabetes on a daily basis.

Online Resources/Chat Rooms

Diabetic-Lifestyle Just for Kids
www.diabetic-lifestyle.com/forkids.htm

Children with DIABETES
www.childrenwithdiabetes.com

Diabetes Chat
www.diabetesCHAT.net
Must be 18 years old to participate

Medical Alert Jewelry

Diabetes Research & Wellness Foundation
FREE diabetes ID necklaces
www.diabeteswellness.net/
Medication Assistance & Information

Abbot Diabetes Patient Assistance Program
866-224-8887
www.abbottdiabetescare.com

Access Diabetic Supply
1901 Green Road, Suite A
Deerfield Beach, FL 33064
1-800-715-5031 (Tel)
1-800-276-0252 (Fax)
www.diabeticsupply.com

American Diabetes Supply, Inc.
1-800-453-9033, ext. 611
www.americandiabetessupply.com

American Diabetes Wholesale
1121 S Military Trail
Suite 355
Deerfield Beach, FL 33442
Ph. (Toll Free) – (877) 241-9002
Fax (Toll Free) – (866) 995-4820
www.americandiabeteswholesale.com

B-Scientific Diabetes Centre
800-544-5969
877-505-5545 (fax)
www.bscientific.com
Serves Medicaid, CHIP, CSHCN, & commercial enrollees

Better Living Now, Inc.
500 Wheeler Road
Hauppauge, New York 11788
1-800-854-5729 – Customer Service
1-800-654-7515 – Customer Service Fax Line
1-800-756-8775 – Sales
www.betterlivingnow.com

CCS Medical
14255 49th Street North, Suite 301
Clearwater, FL 33762
1-800-726-9811
Care Entrée
972-522-2000
www.careentree.com

Edgepark Medical Supplies Shop
1-800-321-0591
www.edgepark.com/

Focus Express Mail Pharmacy Inc.
1250 Easton Road
Suite S-101
Horsham, PA 19044
1-866-403-6287
www.focuspharmacy.com

Free Drug Card
www.freedrugcard.us

Free Medicine Foundation
573-996-3333
www.freemedicinefoundation.com/index.html

Free Medicine Program
800-921-0072
www.freemedicineprogram.com

FREEDOMED
1-888-722-7556
www.freedomed.com

The Health and Wellness Education Center
205-652-6557
tydebra3@aol.com

Liberty Medical Supply Pharmacy
10400 S. Federal Hwy., Suite 200
Port St. Lucie, FL 34952
www.libertymedical.com

Current or Future Patients
Diabetes Products and Services 1-800-376-1599
To Reorder Diabetes Supplies 1-888-537-7726
To Reorder Insulin and Syringes 1-800-599-9680
HbA1c Test Kits 1-877-891-7765
Prescription Medication Mailing Service
1-800-597-8635
Healthcare Professionals
Diabetes Products and Services 1-866-836-9935
HbA1c Test Kits 1-800-545-0916
Prescription Medication Mailing Service
1-866-238-9469

Medicare Prescription Drug Plans
800-633-4227
www.medicare.gov/MPDPF/Shared/Static/Resources.asp

The Medicine Program
866-694-3893
www.themedicineprogram.com

Medicool, Inc.
20460 Gramercy Pl
Torrance, California 90501
1-800-433-2469
www.medicool.com/diabetes

Mini Pharmacy & Medical Supplies
1-888-545-6464
www.minipharmacy.net/index.php

National Diabetes Information Clearinghouse
1-800-860-8747
1 Information Way
Bethesda, MD 20892-3560

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
800-860-8747
Publication: “Financial Help for Diabetes Care”

NeedyMeds
www.needymeds.com

Partnership for Prescription Assistance (PPA)
1-888-477-2669
www.pparx.org

Pharmacy Distributor Services, Inc.
112 Intracoastal Pointe Drive
Jupiter, FL 33477
Tel: 1-800-440-2417
Fax: 1-800-590-3441
www.pharmacydistributorservices.com
RxAssist
www.rxassist.org

State Pharmaceutical Assistance Programs
www.ncsl.org/programs/health/drugaid.htm

Together RX
1-800-865-7211
www.Together-RX.com

Veterans Prescription Service
877-222-8387
www.va.gov/healtheligibility

Western Diabetic Supplies
1140 36th St - Suite 140
Ogden, Utah 84403
Ph: 877-937-8342
Fax: 866-808-3418
www.westerndiabeticsupplies.com

Pharmaceutical Companies Assistance Programs

Amylin Pharmaceuticals, Inc.
Amylin Patient Assistance Program
Phone – 1-800-330-7647

AztraZeneca Pharmaceuticals, LP
AstraZeneca Foundation Patient Assistance Program
Phone – 1-800-292-6363

Aventis Pharmaceuticals Inc.
Sanofi-Aventis Patient Assistance Program
Phone – 1-800-221-4025

Bayer Pharmaceuticals Corporation
Bayer Patient Assistance Program
Phone – 1-800-998-9180

Bristol-Myers Squibb Company
Bristol-Myers Squibb Patient Assistance Foundation, Inc.
Phone – 1-800-736-0003

Eli Lilly and Company
Lilly Cares
Phone – 1-800-545-6962
GlaxoSmithKline
Bridges to Access
Phone – 1-866-728-4368

Johnson & Johnson
Health Care Systems Patient Assistance Program
Phone – 1-800-652-6227

Merck Patient Assistance Program
Phone - 1-800-994-2111

Merck/Scherling-Plough Pharmaceuticals
Merck/Scherling-Plough Patient Assistance Program
Phone – 1-800-347-7503

Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation Patient Assistance Program
Phone – 1-800-277-2254

Novo Nordisk Inc.
Novo Nordisk Diabetes Patient Assistance Program
Phone – 1-866-310-7549

Pfizer
866-776-3700
www.pfizerhelpfulanswers.com
2 programs: Connection to Care, &Pfizer Pfriends — not age-mandated
Note: Cannot have insurance to qualify for this program

Roche Laboratories Inc.
Roche Laboratories Patient Assistance Program
Phone – 1-877-757-6243

Sanofi-Aventis
Sanofi-Aventis Patient Assistance Program
Phone – 1-800-221-4025

Scherling-Plough Corporation
SP-Cares Patient Assistance Program
Phone – 1-800-656-9485

Takeda Pharmaceuticals North America, Inc.
Takeda Patient Assistance Program
Phone – 1-800-830-9159 or 1-877-582-5332
Eye Care Assistance

American Foundation for the Blind
11 Penn Plaza, Suite 300
New York, New York 10001
1-800-232-5463
212-502-7600
afbinfor@afb.net
wwwafb.org

Eye Care America
655 Beach St.
San Francisco, CA 94109-1336
1-800-222-3937
wwweyecareamerica.org
Note: Also provides assistance with medications

Blindness Education, Screening, and Treatment (BEST) Program
Division for Blind Services
Texas Department of Assistive and Rehabilitative Services (DARS)
1-800-628-5115
wwwdarsstate.txus/ dbs/best/
DBSinfo@darsstate.txus

Lighthouse International
111 East 59th Street
New York, New York 10022-1202
1-800-334-5497
1-800-829-0500
212-821-9200
212-821-9713 (TDD)
info@lighthouse.org
wwwlighthouse.org

National Association for Visually Handicapped (NAVH)
22 West 21st Street, 6th Floor
New York, New York 10010-6493
212-889-3141
wwwnavh.org
National Eye Institute
National Institutes of Health
2020 Vision Place
Bethesda, MD 20892-3655
301-496-5248
2020@nei.nih.gov
www.nei.nih.gov

National Federation of the Blind
1800 Johnson Street
Baltimore, MD 21230
Phones: 1-888-581-4741, 410-659-9314
Fax: 410-685-5653
www.nfb.org

Prevent Blindness America
500 East Remington Road
Schaumburg, IL 60173-4557
1-800-331-2020
847-843-2020
info@preventblindness.org
www.preventblindness.org

Advocacy

Advocacy, Inc.
7800 Shoal Creek Blvd., #171-E
Austin, TX 78757-1024
1-800-252-9108

Patient Advocate Foundation
800-532-5274
www.patientadvocate.org

Children’s Resources

Children with Diabetes
www.childrenwithdiabetes.com

Marathon Kids
www.marathonkids.org

Shriners Hospitals
800-237-5055
Texas Children’s Hospital
832-822-3670
www.texaschildrenshospital.org/CareCenter/Diabetes

Camps

ADA Diabetes Camps
www.diabetes.org/communityprograms-and-localevents/diabetescamps.jsp
Each summer, there are day camps and 1- to 3-week camping sessions for children with type 1 diabetes.
Tuition assistance is available based on financial need.

Camp Bluebonnet
Sponsor: Children’s Diabetes Camp of Central Texas
Contact: Amy Wallquist
P.O. Box 12885
Austin, TX 78711-2885
Email: camp_bluebonnet@yahoo.com
www.childrensdiabetescamp.org
Day camp for children with diabetes, ages 4-17

Camp Sweeney
P. O. Box 918
Gainesville, TX 76273
940-665-2011/Fax: 940-665-9467
www.campsweeney.org/
Summer camping sessions from 10 days to 3 weeks for children ages 5-19 with type 1 diabetes.
Family weekend camp and winter session offered. Camperships available.

Texas Lions Camp
P.O. Box 247
Kerrville, Texas 78029-0247
1-830-896-8500/ Fax: 830-896-3666
www.lionscamp.com/Diabetes.htm
Two FREE summer camping sessions exclusively for children ages 8-15 that use insulin. Sponsored by Texas Districts of Lions Clubs International.

Government Resources

Centers for Disease Control
Division of Diabetes Translation
www.cdc.gov
National Institutes of Health  
www.nih.gov

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)  
www.niddk.nih.gov

National Diabetes Education Program  
www.ndep.nih.gov

General Information

Maternal and Child Health Library  
www.mchlibrary.info/KnowledgePaths/kp_diabetes.html

Language Translation

CDC’s “Take Charge of Your Diabetes” is available in 9 languages.
For translations, access the following link:

Pump Training

IPump.org, Inc.  
program-director@ipump.org  
www.ipump.org/  
IPump.org provides temporary financial assistance and FREE supplies to people of all ages with diabetes in need throughout the U.S.
Animas: Animas Pump Company 1-877-937-7867
MiniMed: Medtronic 1-800-999-9859
Cosmo: Smiths Medical 1-800-544-4734
Omnipod: Insulet Corporation 1-800-544-4734

Primary Care Service Sites

Texas Association of Community Health Centers  
www.tachc.org

U.S. Department of Health and Human Services (DHHS)  
Health Resources and Services Administration (HRSA)  
ask.hrsa.gov/pc/
Support Services

Family Support Network
www.childrenwithdiabetes.com/fsn/

Insurance Information

Health Insurance Consumer Guides
www.healthinsuranceinfo.net

Insure Kids Now!
877-543-7669
www.insurekidsnow.gov

Medicaid
1-877-267-2323

State Children’s Health Insurance Program
1-877-543-7669
www.cms.hhs.gov/home/schip.asp

The Texas Department of Insurance
333 Guadalupe
Austin 78701

or
P.O. Box 149104
Austin 78714-9104
800-578-4677 (in Texas), 512-463-6169

Consumer Helpline
1-800-252-3439, 463-6515 in Austin
www.tdi.state.tx.us